Enfusion (ENFN) 10-K 30 Mar 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 29, 2022	Jun. 30, 2021
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-40949
Entity Registrant Name	ENFUSION, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-1268462
Entity Address State Or Province	IL
Entity Address, Address Line One	125 South Clark Street
Entity Address, Address Line Two	Suite 750
Entity Address, City or Town	Chicago
Entity Address, Postal Zip Code	60603
City Area Code	312
Local Phone Number	253-9800
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Entity Public Float			$ 0
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Title of 12(b) Security	Class A common stock, par value $0.001 per share
Trading Symbol	ENFN
Security Exchange Name	NYSE
Entity Central Index Key	0001868912
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
Auditor Name	Ernst & Young LLP
Auditor Firm ID	42
Auditor Location	Chicago, Illinois
Common Class A
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		65,583,289
Common Class B
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		47,470,972

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 64,365	$ 13,938
Accounts receivable, net of allowance for doubtful accounts	18,223	12,180
Prepaid expenses and other current assets	7,090	2,793
Total current assets	89,678	28,911
Property and equipment, net	13,051	8,784
Other assets	3,356	1,404
Total assets	106,085	39,099
Current liabilities:
Accounts payable	2,528	484
Accrued expenses and other current liabilities	5,578	7,666
Current portion of long-term debt		2,500
Total current liabilities	8,106	10,650
Long-term debt, net of discount and issuance costs		96,063
Other liabilities	538	430
Total liabilities	8,644	107,143
Commitments and contingencies
Preferred Units:
Total Preferred Units		165,515
Stockholders' Equity/Members' deficit:
Members' deficit, no par value, 47.968 Units issued and outstanding as of December 31, 2020		(233,347)
Preferred stock, par value $0.001 per share, 100,000,000 shares authorized, no shares issued and outstanding as of December 31, 2021
Additional paid-in capital	226,717
Accumulated deficit	(171,209)
Accumulated other comprehensive loss	(325)	(212)
Total Stockholders' Equity attributable to Enfusion, Inc. /Members' deficit	55,296	(233,559)
Non-Controlling Interests	42,145
Total Stockholders' Equity/ Members' deficit	97,441	(233,559)
Total liabilities, Preferred Units and Stockholders' Equity/Members' deficit	106,085	39,099
Common Class A
Stockholders' Equity/Members' deficit:
Common stock	66
Common Class B
Stockholders' Equity/Members' deficit:
Common stock	$ 47
Class C-1 Units
Preferred Units:
Total Preferred Units		6,434
Class C-2 Units
Preferred Units:
Total Preferred Units		44,863
Class D Units
Preferred Units:
Total Preferred Units		$ 114,218

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Preferred units, outstanding (in shares)		53.774
Units Par value (in dollars per share)		$ 0
Units issued (in share)		47.968
Units outstanding (in share)		47.968
Preferred stock par value (in dollars per share)	$ 0.001
Preferred stock authorized	100,000,000
Preferred stock, shares issued	0
Preferred stock outstanding	0
Common Class A
Common stock par value (in dollars per share)	$ 0.001
Common stock, shares authorized	1,000,000,000
Common stock, shares issued	65,583,289
Common stock, shares outstanding	65,583,289
Common Class B
Common stock par value (in dollars per share)	$ 0.001
Common stock, shares authorized	150,000,000
Common stock, shares issued	47,470,972
Common stock, shares outstanding	47,470,972
Class C-1 Units
Preferred units, par value (in dollars per share)		$ 0
Preferred units, issued (in shares)		28.777
Preferred units, outstanding (in shares)		28.777
Class C-2 Units
Preferred units, par value (in dollars per share)		$ 0
Preferred units, issued (in shares)		12.219
Preferred units, outstanding (in shares)		12.219
Class D Units
Preferred units, par value (in dollars per share)		$ 0
Preferred units, issued (in shares)		12.778
Preferred units, outstanding (in shares)		12.778

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
REVENUES:
Total revenues	$ 111,700	$ 79,565	$ 59,027
COST OF REVENUES:
Total cost of revenues	31,845	21,358	16,961
Gross profit	79,855	58,207	42,066
OPERATING EXPENSES:
General and administrative	150,614	35,888	16,625
Sales and marketing	51,725	9,927	7,426
Technology and development	153,400	6,318	4,146
Total operating expenses	355,739	52,133	28,197
(Loss) income from operations	(275,884)	6,074	13,869
NON-OPERATING INCOME (EXPENSE):
Interest expense	(4,594)	(1,662)	(724)
Other income (expense)	(1,185)	82	(3)
Total non-operating income (expense)	(5,779)	(1,580)	(727)
(Loss) income before income taxes	(281,663)	4,494	13,142
Income tax expense	579	433	486
Net (loss) income	(282,242)	4,061	12,656
Net loss attributable to non-controlling interests	(123,925)
Net loss attributable to Enfusion, Inc.	$ (158,317)	4,061	12,656
Net loss per Class A common shares attributable to Enfusion, Inc.:
Net loss per Class A common shares attributable to Enfusion, Inc., Basic	$ (2.26)
Net loss per Class A common shares attributable to Enfusion, Inc., Diluted	$ (2.26)
Weighted Average number of Class A common shares outstanding:
Weighted Average number of Class A common shares outstanding, Basic	83,045
Weighted Average number of Class A common shares outstanding, Diluted	83,045
Platform subscriptions
REVENUES:
Total revenues	$ 103,259	73,550	55,877
COST OF REVENUES:
Total cost of revenues	27,195	18,015	13,698
Managed services
REVENUES:
Total revenues	7,119	4,436	2,379
COST OF REVENUES:
Total cost of revenues	4,425	2,512	2,563
Other
REVENUES:
Total revenues	1,322	1,579	771
COST OF REVENUES:
Total cost of revenues	$ 225	$ 831	$ 700

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net (loss) income	$ (282,242)	$ 4,061	$ 12,656
Other comprehensive loss, net of income tax:
Foreign currency translation loss	(90)	(116)	(86)
Total other comprehensive (loss) income	(282,332)	3,945	12,570
Comprehensive loss attributable to non-controlling interests	(123,902)
Total comprehensive (loss) income attributable to Enfusion, Inc.	$ (158,430)	$ 3,945	$ 12,570

Consolidated Statements of Pref

Consolidated Statements of Preferred Units Stockholders' Equity, and Members' Deficit - USD ($)	Preferred UnitsClass C-1 Units	Preferred UnitsClass C-2 Units	Preferred UnitsClass D Units	Preferred Units	Members' EquityClass A Units	Members' Equity	Common StockCommon Class A	Common StockCommon Class B	Additional Paid-in Capital	Accumulated Deficit/Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interest	Class A Units	Class C-1 Units	Class C-2 Units	Class D Units	Total
Balance at Beginning of period at Dec. 31, 2018											$ (10,000)						$ (44,605,000)
Balance at Beginning of period at Dec. 31, 2018						$ (44,595,000)
Balance at Beginning of period (in shares) at Dec. 31, 2018						67.613
Members' Equity (Deficit)
Net Income (Loss)						$ 8,033,000											8,033,000
Redemption of Units					$ (57,450,000)								$ (57,450,000)
Redemption of Units (in shares)					(13.117)
Other comprehensive (loss) income											(86,000)						(86,000)
Distributions - loan proceeds																	(16,178,000)
Distributions to members						(7,593,000)											(7,593,000)
Balance at end of period at Dec. 31, 2019						$ (117,783,000)
Balance at end of period at Dec. 31, 2019											(96,000)						(117,879,000)
Balance at end of period (in shares) at Dec. 31, 2019						54.496
Balance at Beginning of period at Dec. 31, 2018				$ 54,383,000
Balance at Beginning of period (in shares) at Dec. 31, 2018				32.693
Preferred Units
Issuance of class units net of issuance cost		$ 57,307,000
Issuance of class units net of issuance cost (in shares)		13.117
Net income				$ 4,623,000
Distributions - loan proceeds				(7,822,000)		$ (16,178,000)
Distributions to members				(3,418,000)
Balance at end of period at Dec. 31, 2019				$ 105,073,000
Balance at end of period (in shares) at Dec. 31, 2019				45.810
Members' Equity (Deficit)
Net Income (Loss)						2,201,000											2,201,000
Redemption of Units						$ (76,634,000)											(76,634,000)
Redemption of Units (in shares)						(6.528)
Other comprehensive (loss) income											(116,000)						(116,000)
Distributions - loan proceeds						$ (38,607,000)											(38,607,000)
Distributions to members						(2,524,000)											(2,524,000)
Balance at end of period at Dec. 31, 2020						$ (233,347,000)
Balance at end of period at Dec. 31, 2020											(212,000)						$ (233,559,000)
Balance at end of period (in shares) at Dec. 31, 2020						47.968							47.968				47.968
Preferred Units
Repurchase of units in a non-cash exchange	$ (45,975,000)	$ (10,538,000)
Repurchase of units in a non-cash exchange (in shares)	(3.916)	(0.898)
Issuance of Class D Units in a non-cash exchange, net of issuance costs (in Shares)			4.814
Issuance of Class D Units in a non-cash exchange, net of issuance costs			$ 56,376,000
Issuance of class units net of issuance cost			$ 93,261,000
Issuance of class units net of issuance cost (in shares)			7.964
Net income				$ 1,860,000
Distributions - loan proceeds				(32,454,000)
Distributions to members				(2,088,000)
Balance at end of period at Dec. 31, 2020				$ 165,515,000										$ 6,434,000	$ 44,863,000	$ 114,218,000	$ 165,515,000
Balance at end of period (in shares) at Dec. 31, 2020				53.774										28.777	12.219	12.778	53.774
Members' Equity (Deficit)
Net Income (Loss)						$ 6,078,000											$ 6,078,000
Other comprehensive (loss) income											(145,000)						(145,000)
Distributions to members						(1,476,000)											(1,476,000)
Balance at end of period at Oct. 20, 2021						$ (228,745,000)
Balance at end of period at Oct. 20, 2021											(357,000)						(229,102,000)
Balance at end of period (in shares) at Oct. 20, 2021						47.968
Preferred Units
Net income				$ 6,814,000
Distributions to members				(1,807,000)
Balance at end of period at Oct. 20, 2021				$ 170,522,000
Balance at end of period (in shares) at Oct. 20, 2021				53.774
Balance at Beginning of period at Dec. 31, 2020											(212,000)						$ (233,559,000)
Balance at Beginning of period at Dec. 31, 2020						$ (233,347,000)
Balance at Beginning of period (in shares) at Dec. 31, 2020						47.968							47.968				47.968
Members' Equity (Deficit)
Issuance of Class A common stock in the IPO, net of issuance costs																	$ 260,545,000
Purchase of common units from Pre-IPO common unit holders																	(87,846,000)
Balance at end of period at Dec. 31, 2021							$ 66,000	$ 47,000	$ 226,717,000	$ (171,209,000)	(325,000)	$ 42,145,000					97,441,000
Balance at end of period (in shares) at Dec. 31, 2021							65,583,289	47,470,972
Balance at Beginning of period at Dec. 31, 2020				$ 165,515,000										$ 6,434,000	$ 44,863,000	$ 114,218,000	$ 165,515,000
Balance at Beginning of period (in shares) at Dec. 31, 2020				53.774										28.777	12.219	12.778	53.774
Balance at Beginning of period at Oct. 20, 2021											(357,000)						$ (229,102,000)
Balance at Beginning of period at Oct. 20, 2021						$ (228,745,000)
Balance at Beginning of period (in shares) at Oct. 20, 2021						47.968
Members' Equity (Deficit)
Net Income (Loss)										(171,209,000)		(123,925,000)					(295,134,000)
Other comprehensive (loss) income											32,000	23,000					55,000
Effect of the Reorganization Transactions						$ 228,745,000	$ 49,000	$ 53,000	(27,941,000)			(30,384,000)					170,522,000
Effect of the Reorganization Transactions, shares						(47.968)	48,744,182	52,997,579
Issuance of Class A common stock in the IPO, net of issuance costs							$ 17,000		143,628,000			116,065,000					259,710,000
Issuance of Class A common stock in the IPO, net of issuance costs (in shares)							16,839,107
Purchase of common units from Pre-IPO common unit holders								$ (6,000)	(50,956,000)			(36,884,000)					(87,846,000)
Purchase of common units from Pre-IPO common unit holders								(5,526,607)
Share-based compensation, net of taxes paid									161,986,000			117,250,000					279,236,000
Balance at end of period at Dec. 31, 2021							$ 66,000	$ 47,000	$ 226,717,000	$ (171,209,000)	$ (325,000)	$ 42,145,000					$ 97,441,000
Balance at end of period (in shares) at Dec. 31, 2021							65,583,289	47,470,972
Balance at Beginning of period at Oct. 20, 2021				$ 170,522,000
Balance at Beginning of period (in shares) at Oct. 20, 2021				53.774
Preferred Units
Effect of the Reorganization Transactions				$ (53.774)
Effect of the Reorganization Transactions (Shares)				(170,522,000)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net (loss) income	$ (282,242)	$ 4,061	$ 12,656
Adjustments to reconcile Net income to Net cash provided by operating activities:
Depreciation and amortization	3,975	2,291	1,157
Provision for bad debts	1,450	1,010	266
Amortization of debt-related costs	222	60	22
Stock-based compensation expense	289,803
Loss on extinguishment of debt	1,215
Net foreign currency losses		1	3
Change in operating assets and liabilities:
Accounts receivable	(7,493)	(4,216)	(2,790)
Prepaid expenses and other assets	(6,477)	(1,776)	(951)
Accounts payable	2,044	41	231
Accrued expenses and other liabilities	(2,815)	193	1,712
Net cash (used in) provided by operating activities	(318)	1,665	12,306
Cash flows from investing activities:
Purchases of property and equipment	(8,014)	(5,068)	(4,429)
Net cash (used in) investing activities	(8,014)	(5,068)	(4,429)
Cash flows from financing activities:
Proceeds from term loan		71,211	29,700
Proceeds from draw on revolving debt facility		1,800
Redemption of Class A Units		(76,634)	(57,450)
Distribution of loan proceeds to Members		(71,061)	(24,000)
Repayment of term loan	(100,000)	(300)	(2,000)
Repayment of draw on revolving debt facility		(1,800)
Payment of Member distributions	(3,283)	(4,612)	(11,011)
Payment of equity issuance costs on non-cash issuance of Class D Units		(137)
Payment of debt issuance and debt facility costs		(169)	(87)
Issuance of Class A common stock in the IPO, net of issuance costs	260,545
Purchase of common units from Pre-IPO common unit holders	(87,846)
Payment of withholding taxes on stock-based compensation	(10,567)
Net cash provided by (used in) financing activities	58,849	11,559	(7,541)
Effect of exchange rate changes on cash	(90)	(116)	(86)
Net increase in cash	50,427	8,040	250
Cash, beginning of period	13,938	5,898	5,648
Cash, end of period	64,365	13,938	5,898
Supplemental disclosure of cash flow information:
Interest paid in cash	4,813	1,492	588
Supplemental disclosure of non-cash financing activities:
Issuance of Class D Units in a non-cash exchange for Class C-1 and C-2 Units		56,376
Effect of the Reorganization Transactions	58,223
IPO costs included in Accrued expenses and other liabilities	$ 835
Class C-2 Units
Cash flows from financing activities:
Issuance of Units, net of issuance costs			$ 57,307
Class D Units
Cash flows from financing activities:
Issuance of Units, net of issuance costs		$ 93,261

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2021
Organization and Description of Business
Organization and Description of Business	ENFUSION, INC. Notes to Consolidated Financial Statements Note 1 Organization and Description of Business Enfusion, Inc. (“Enfusion” or the “Company”) is a leading provider of cloud-based order and execution management, portfolio management and risk systems. Enfusion’s clients include large global hedge fund managers, institutional asset managers, family offices and other institutional investors. Enfusion provides its clients with innovative real-time performance, risk calculations, and accounting capabilities for some of the most sophisticated financial products. The Company is headquartered in Chicago, Illinois and has offices in Chicago, New York, London, Dublin, Hong Kong, Singapore, São Paulo, Mumbai, Bengaluru, and Sydney.

Principles of Consolidation and

Principles of Consolidation and Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Principles of Consolidation and Basis of Presentation
Principles of Consolidation and Basis of Presentation	Note 2 Principles of Consolidation and Basis of Presentation Initial Public Offering and Reorganization Enfusion, Inc. was incorporated in Delaware on June 11, 2021 for the purpose of facilitating an initial public offering and other related transactions in order to carry on the business of Enfusion Ltd. LLC. On October 25, 2021, Enfusion, Inc. completed an initial public offering of 21,562,500 shares of its Class A common stock at a public offering price of $17.00 per share (the “IPO”), receiving approximately $259.7 million in net proceeds, after deducting the underwriting discount and offering expenses, which were used, among other things, to purchase 5,526,607 newly-issued LLC units from Enfusion Ltd. LLC at a price per unit equal to the initial public offering price per share of Class A common stock in the IPO, less the underwriting discount and estimated offering expenses. In connection with the Company’s IPO, the Company completed a series of organizational transactions (the “Reorganization Transactions”). As a result of the Reorganization Transactions: ● The certificate of incorporation of Enfusion, Inc. was amended and restated to, among other things, provide for 1,000,000,000 authorized shares of Class A common stock,150,000,000 authorized shares of Class B common stock, and 100,000,000 shares of preferred stock ● The Amended and Restated Operating Agreement of Enfusion Ltd. LLC (the “LLC Operating Agreement”) was amended and restated to, among other things, modify its capital structure by reclassifying each of the outstanding units held by the Pre-IPO Common Unitholders into a new class of LLC interests (or “Common Units”), issued on a 1,000,000 to 1 basis; ● Pursuant to the adoption of the LLC Operating Agreement, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., was appointed the sole managing member of Enfusion Ltd. LLC; ● Pre-IPO Shareholders acquired 48,744,182 shares of the Company’s Class A common stock through certain restructuring transactions in exchange for their ownership interests in the Blocker Companies and Enfusion, Inc., indirectly through three new wholly-owned subsidiaries, acquiring an equal number of outstanding Common Units; ● The Company entered into a Tax Receivable Agreement with certain of the Company’s Pre-IPO Owners that provides for the payment by Enfusion, Inc. to such Pre-IPO Owners of 85% of the benefits, if any, that Enfusion, Inc. actually realizes, or is deemed to realize (calculated using certain assumptions) as a result of (i) existing tax basis acquired in the IPO, (ii) increases in existing tax basis and adjustments to the basis of the tangible and intangible assets of Enfusion Ltd. LLC as a result of sales or exchanges (or deemed exchanges) of Common Units for shares of Class A common stock or distributions (or deemed distributions) with respect to Common Units after the IPO, (iii) Enfusion, Inc.’s utilization of certain tax attributes of the Blocker Companies, and (iv) certain other tax benefits related to entering into the Tax Receivable Agreement, including tax benefits attributable to payments under the Tax Receivable Agreement. Enfusion, Inc. retains the benefit of the remaining 15% of the tax savings. Enfusion, Inc. now has three wholly-owned subsidiaries: Enfusion US1, Inc., Enfusion US2, Inc. and Enfusion US3, Inc.; as well as a substantial financial interest in Enfusion Ltd. LLC and its wholly-owned subsidiaries: Enfusion Systems UK Ltd, Enfusion HK Limited, Enfusion Software Limited, Enfusion Softech India Private Limited, Enfusion (Singapore) Pte. Limited, Enfusion do Brasil Tecnologia da Informacao Ltda, Enfusion (Australia) Pty. Ltd. and Enfusion (Shanghai) Co., Ltd. Enfusion, Inc., through its control over the managing member of Enfusion Ltd. LLC, manages and operates Enfusion Ltd. LLC’s business and controls its strategic decisions and day-to-day operations. As such, Enfusion, Inc. consolidates the financial results of Enfusion Ltd. LLC, and a portion of Enfusion, Inc.’s net income will be allocated to non-controlling interests to reflect the entitlement of the Pre-IPO Common Unitholders to a portion of Enfusion Ltd. LLC’s net income. As of December 31, 2021, we owned approximately 58% of Enfusion Ltd. LLC. Principles of Consolidation The Reorganization Transactions were accounted for as a reorganization of entities under common control. As a result, the consolidated financial statements of Enfusion, Inc. recognized the assets and liabilities received in the Reorganization Transactions at their historical carrying amounts, as reflected in the historical financial statements of Enfusion Ltd. LLC. Accordingly, the financial statements for periods prior to the IPO and the Reorganization Transactions have been adjusted to combine the previously separate entities for presentation purposes. These statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions are eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and various other assumptions believed to be reasonable. These estimates and assumptions include, but are not limited to, judgments affecting the measurement of the payable to related parties pursuant to the Tax Receivable Agreement, amortization periods, certain assumptions used in the valuation of stock-based compensation, assessment of the allowance for doubtful accounts, and accounting for income taxes and assessment of valuation allowances. Actual results could differ from those estimates. ​ The Company’s results can also be affected by economic, political, legislative, regulatory and legal actions, including but not limited to health epidemics and pandemics and the resulting economic impact, including the impact from the COVID-19 pandemic. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, and government fiscal policies can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities and carries various levels of insurance, the Company could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings. ​ Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the CODM. While the Company operates in multiple countries, the Company’s business operates as one operating segment because most of the Company’s service offerings are delivered and supported on a global basis, the Company’s service offerings are deployed in a nearly identical way, and the Company’s CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 3 Summary of Significant Accounting Policies The significant accounting policies of the Company and its subsidiaries are summarized below. Cash Cash includes cash in banks, cash on hand, and overnight deposits. Accounts Receivable Accounts receivable includes billed and unbilled receivables, net of allowance of doubtful accounts. Billed accounts receivable are initially recorded upon the invoicing to clients with payment due within 30 days. Unbilled accounts receivable represent revenue recognized on contracts for which the timing of invoicing to clients differs from the timing of revenue recognition. As of December 31, 2021 and 2020, unbilled accounts receivable was $1.3 million and $349 thousand, respectively. The unbilled accounts receivable balance is due within one year. The Company maintains an allowance for doubtful accounts at an amount estimated to be sufficient to provide adequate protection against losses resulting from extending credit to its clients. The Company regularly determines the adequacy of the allowance based on its assessment of the collectability of the accounts receivable by considering the age of each outstanding invoice, the collection history of each client, and an evaluation of current expected risk of credit loss of any clients with known financial difficulties. The Company assesses collectability by reviewing accounts receivable on an aggregated basis where similar characteristics exist and on an individual basis for specific clients with historical collectability issues or known financial difficulties. Increases to the allowance are recognized as a charge to doubtful accounts included in General and administrative expenses in the consolidated statement of operations. Accounts receivable deemed uncollectible are charged against the allowance for doubtful accounts when identified. The Company's allowances are as follows (in thousands): ​ ​ ​ ​ ​ Balance at December 31, 2019 ​ $ 95 Charges to the provision ​ ​ 1,010 Accounts written off, net of recoveries ​ (507) Balance at December 31, 2020 ​ 598 Charges to the provision ​ 1,450 Accounts written off, net of recoveries ​ (1,257) Balance at December 31, 2021 ​ $ 791 ​ Property and Equipment, Net Property and equipment is stated at historical cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the individual assets, except for leasehold improvements, which are depreciated over the shorter of the estimated useful life of the asset or the underlying lease term. Also included in property and equipment are capitalized costs of software developed for internal use. The useful lives of property and equipment are as follows: ​ ​ ​ Property and Equipment Asset Type Estimated Useful Lives Software development costs 3 years Computers and equipment 5 years Furniture and fixtures 5 years Leasehold improvements Shorter of estimated economic useful life or remaining lease term ​ Maintenance and repairs are expensed as incurred. Upon retirement or disposition, the cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is included in operating income. Software Development Costs Capitalized software costs consist of costs to purchase software to be used within the Company and costs to develop software internally. Capitalization of purchased or internally developed software occurs during the application development stage and consists of design, coding and testing. Amortization of software development costs is calculated using the straight-line method over the estimated useful lives of the software, which is generally three years. Capitalized software development costs are recorded within property and equipment, net of accumulated amortization, within the consolidated balance sheets. Amortization expense is included in Cost of revenues – platform subscription services in the consolidated statements of operations. Impairment of Long-Lived Assets The Company evaluates the carrying value of long-lived assets, including identifiable intangibles, in accordance with the accounting standard for impairment or disposal of long-lived assets, which requires recognition of impairment of long-lived assets in the event that circumstances indicate impairment may have occurred and when the net carrying value of such assets exceeds the future undiscounted cash flows attributed to such assets. The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. No impairment of long-lived assets occurred during the years ended December 31, 2021, 2020 and 2019. Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the exit price) in an orderly transaction between market participants at the measurement date. Accounting standards establish a hierarchal framework, which prioritizes and ranks the level of market price observability used in measuring assets and liabilities at fair value. Market price observability is impacted by a number of factors, including the type of investment and the characteristics specific to the investment. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on the best information available. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories: Level 1 Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 Inputs are inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and Level 3 Inputs are unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. As of December 31, 2020, the carrying value of the Company’s long-term debt approximated its fair value, which represents a Level 2 fair value measurement. The carrying amount of the Company’s other financial instruments, including accounts receivable and accounts payable, approximate fair value due to their short-term nature. Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue Recognition Historically, platform subscription contracts have typically had a one-year term and were cancellable with 30 days’ notice, though our more recent contracts have typically been for multi-year terms without cancellation for convenience. Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework: ● Identification of the contract, or contracts, with a client; ● Identification of the performance obligation in the contract; ● Determination of transaction price; ● Allocation of the transaction price to the performance obligations in the contract; and ● Recognition of revenue when, or as, performance obligations are satisfied. Platform subscription revenues Platform subscription revenues consist primarily of fees for providing clients with access to the Company’s cloud-based platform. Platform subscription clients do not have the right to take possession of the platform’s software, and do not have any general return rights. Platform subscription revenues are generally recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date that the client gains access to the platform. Installment payments are invoiced at the end of each calendar month during the subscription term. Managed services revenues Managed services revenues primarily consist of client-selected middle and back-office services provided on our clients’ behalf using the Company’s platform. Revenue is recognized monthly as the managed services are performed, with invoicing occurring at the end of the calendar month. Other revenues Other revenues consists of non-subscription-based revenues, such as software enhancements developed for individual, sponsoring clients, but received by all clients, and data conversion and services that integrate a client’s historical data into our solution. We recognize revenues monthly as these services are performed with invoicing occurring at the end of each month. Service contracts with multiple performance obligations Our service contracts with clients can include multiple performance obligations. For these contracts, we account for individual performance obligations separately if they are distinct. However, all distinct performance obligations within a contract are satisfied over a similar period of time with the same measure of progress. Accordingly, each distinct performance obligation within a contract has the same pattern of revenue recognition. We have determined that implementation services are not distinct from the ongoing platform subscription services due to the highly specialized knowledge required to execute on our solution. Such services are recognized with the platform subscription services revenue over time. Disaggregation of revenue The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following table: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 Geographic Region Amount Percent Amount Percent ​ Amount Percent Americas* ​ $ 72,994 65.3% ​ $ 54,057 67.9% ​ $ 42,158 71.4% Europe, Middle East and Africa (EMEA) ​ 13,491 12.1% ​ 8,748 11.0% ​ 6,727 11.4% Asia Pacific (APAC) ​ 25,215 22.6% ​ 16,760 21.1% ​ 10,142 17.2% Total revenues ​ $ 111,700 100.0% ​ $ 79,565 100.0% ​ $ 59,027 100.0% ​ * Includes revenues in the United States (country of domicile) of $71.9 million, $53.0 million and $41.4 million for the years ended December 31, 2021, 2020 and 2019, respectively. Remaining performance obligations The Company has elected not to disclose the amount of the transaction price allocated to remaining performance obligations for contracts with an initial term of one year or less, which is the majority of the Company’s contracts. For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of December 31, 2021 was $23.4 million. The Company expects to recognize this amount over the next one Deferred commissions The Company pays sales commissions for initial contracts and expansions of existing contracts with customers. These commissions earned by certain of our sales force are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions paid where the amortization period is one year or less are expensed as incurred. All other sales commissions are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be three years. We determined the period of benefit by taking into consideration our standard contract terms and conditions, rate of technological change, and other factors. Amortization expense is included in sales and marketing expense in the accompanying consolidated statements of operations. The balance of deferred commissions as of December 31, 2021 was $1.7 million and is included in Other assets on the Consolidated Balance Sheets. The amount of amortization expense recognized during the year ended December 31, 2021 was $228 thousand. Deferred commissions and amortization expense were not recorded for the year ended December 31, 2020, as the commissions earned under the prior year commission program were not incremental and recoverable costs of obtaining contracts with customers. Cost of revenues Cost of revenues consists primarily of personnel-related costs associated with the delivery of the Company’s software and services, including base salaries, bonuses, employee benefits and related costs, Additionally, cost of revenues includes amortization of capitalized software development costs, allocated overhead and certain direct data and hosting costs. Research and Development Research and development expenses consist primarily of employee-related expenses for the Company’s software development. Additional expenses include costs related to the development, maintenance, quality assurance and testing of new technologies, and ongoing refinement of the Company’s existing solutions. Research and development expenses, other than internal-use software costs qualifying for capitalization, including costs associated with preliminary project stage activities, training, maintenance, and all other post-implementation stage activities are expensed as incurred. Advertising Costs The Company expenses advertising costs as incurred. Advertising costs incurred were approximately $1.2 million, $1.3 million and $464 thousand during the years ended December 31, 2021, 2020 and 2019, respectively. Leases The Company leases office facilities under operating leases and data centers under service agreements, and accounts for those leases in accordance with ASC 840, Leases Equity-Based Compensation Prior to the IPO, the Company had a Change in Control Bonus Plan (the “Plan”) for certain members of the Company’s management (“Plan Participants”) that provided for the payment of a cash bonus based on a specified number of Management Incentive Award Units (“Award Units”) in the event of a change in control (“CiC”) transaction (i.e., a liquidity event), as defined by the Company’s Operating Agreement. As of December 31, 2020 and December 31, 2019, respectively, the Company did not record a liability for payments under the Plan as the timing of any future CiC transaction or amount of Award Units to be paid to Plan Participants was not probable or estimable. In October 2021, the Company's board of managers elected to terminate the Change in Control Bonus Plan (and all Award Units issued thereunder) upon effectiveness of the registration statement for the IPO. In connection with the IPO, we adopted the 2021 Stock Option and Incentive Plan, or 2021 Plan. The 2021 Plan allows our compensation committee to make incentive awards to our officers, employees, directors and service providers. We also adopted the 2021 Employee Stock Purchase Plan, or 2021 ESPP. The Company measures stock compensation expense for its share-based payment awards at fair value on the grant date. The fair value of share-based payment awards is determined using the fair market value of the underlying Class A common stock on the date of grant. The Company applies a discount for lack of marketability, estimated using the Finnerty Model, to the fair value of awards with post-vesting restrictions, which includes the vested shares of Class A common stock and the contingently issuable shares (the “Contingently Issuable Shares”) of Class A common stock issued on the IPO effectiveness date. For RSUs for which vesting is subject to the achievement of a market capitalization hurdle, the Company determines the fair value of these RSUs using a Monte Carlo simulation. The Monte Carlo simulations used to estimate the fair value include subjective assumptions, including the fair value of the underlying common stock, expected volatility of the price of the Company’s common stock, risk-free interest rate, expected dividend yield of common stock, and the Company’s cost of equity capital. We record forfeitures as they occur. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statement of operations based on the estimated fair value of those awards on the grant date or reporting date, if required to be remeasured, and amortized on a straight-line basis over the requisite service period. Earnings (loss) per share Basic earnings (loss) per share is computed by dividing net earnings (loss) attributable to the Company by the number of weighted average shares of Class A common stock outstanding during the period. Diluted earnings (loss) per share is computed by dividing net earnings (loss) attributable to the Company by the number of weighted-average shares of Class A common stock outstanding during the period after adjusting for the impact of securities that would have a dilutive effect on earnings (loss) per share. See Note 12, Income Loss) Per Class A Common Share All earnings (loss) for the period prior to the IPO were entirely allocable to Enfusion LLC, Ltd. and its historic non-controlling interest. Due to the impact of the Reorganization Transactions, the Company’s capital structure for the pre- and post-IPO periods is not comparable. As a result, the presentation of earnings (loss) per share for the periods prior to the IPO and Organizational Transactions is not meaningful and only earnings (loss) per share for the period subsequent to the IPO and Organizational Transactions is presented herein. Non-controlling interest Non-controlling interests represent the portion of profit or loss, net assets and comprehensive income of our consolidated subsidiaries that is not allocable to the Company based on our percentage of ownership of such entities. ​ Income Taxes The Company accounts for income taxes under the asset and liability method, and deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and deferred tax liabilities is recognized in income in the period that includes the enactment date. We recognize deferred tax assets to the extent that it is believed that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations. A valuation allowance is provided if it is determined that it is more likely than not that the deferred tax asset will not be realized. The Company evaluates and accounts for uncertain tax positions using a two-step approach. Recognition (step one) occurs when the Company concludes that a tax position, based solely on its technical merits, is more-likely-than-not to be sustainable upon examination. Measurement (step two) determines the amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. Derecognition of a tax position that was previously recognized would occur when the Company subsequently determines that a tax position no longer meets the more likely-than-not threshold of being sustained. The Company records interest (and penalties where applicable), net of any applicable related income tax benefit, on potential income tax contingencies as a component of Income tax expense in the Consolidated Statements of Operations. Tax Receivable Agreement (TRA) The Company accounts for amounts payable under the TRA in accordance with ASC 450, Contingencies Concentration of Risk Deposits with Financial Institutions The Company has concentrated its credit risk for cash by maintaining deposits in several financial institutions, which may at times exceed amounts covered by insurance provided by the Federal Deposit Insurance Corporation (“FDIC”). The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk related to cash. Accounts Receivable As of December 31, 2021 and 2020, no individual client represented more than 10% of accounts receivable. For the years ended December 31, 2021, 2020 and 2019, no individual client represented more than 10% of the Company’s total revenues. Translation of Foreign Currencies Foreign currency assets and liabilities of the Company’s international subsidiaries are translated using the exchange rates in effect at the balance sheet date. Results from operations are translated using the average exchange rates prevailing throughout the year. The effects of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars are accumulated as part of the foreign currency translation adjustment in Preferred Units and Members’ Equity (Deficit) in the consolidated balance sheets. Recently Adopted Pronouncements In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Softwar Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. Recent Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02 , Leases Leases Codification Improvements to Topic 842, Leases Leases In December 2019, the FASB issued ASU 2019-12, Income Taxes Simplifying the Accounting for Income Taxes In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses Measurement of Credit Losses on Financial Instruments

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2021
Property and Equipment, Net
Property and Equipment, Net	Note 4 Property and Equipment, Net Property and equipment, net consists of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 ​ 2020 Computer equipment and software ​ $ 14,163 ​ $ 8,533 Software development costs ​ 4,866 ​ 2,948 Leasehold improvements ​ 1,947 ​ 1,406 Furniture and fixtures ​ 540 ​ 671 Total property and equipment, cost ​ 21,516 ​ 13,558 Less accumulated depreciation and amortization ​ (8,465) ​ (4,774) Total property and equipment, net ​ $ 13,051 ​ $ 8,784 ​ As of December 31, 2021 and 2020, property and equipment, net located in the United States was $10.4 million and $7.5 million, respectively. The remainder was located in our various international locations. Included in property and equipment are the capitalized costs of software developed and maintained for internal use. Software development costs capitalized during the years ended December 31, 2021 and 2020 were $2.0 million and $1.4 million, respectively. Depreciation and amortization expense related to property and equipment, excluding software development costs, was $2.4 million, $1.5 million and $825 thousand for the years ended December 31, 2021, 2020 and 2019, respectively. Amortization expense related to software development costs was $1.3 million, $759 thousand and $332 thousand for the years ended December 31, 2021, 2020 and 2019, respectively. Estimated future amortization of capitalized software development costs are as follows (in thousands): ​ ​ ​ ​ Year ending December 31, Amount 2022 ​ $ 1,289 2023 ​ 863 2024 ​ 293 Total ​ $ 2,445 ​ ​ ​ ​ ​ ​

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2021
Accrued Expenses and Other Current Liabilities
Accrued Expenses and Other Current Liabilities	Note 5 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Accrued compensation ​ $ 3,180 ​ $ 5,261 Accrued expenses ​ 1,182 ​ 1,478 Accrued taxes ​ 1,216 ​ 414 Accrued interest ​ — ​ 218 Current portion of deferred rent ​ — ​ 29 Other current liabilities ​ — ​ 266 Total accrued expenses and other current liabilities ​ $ 5,578 ​ $ 7,666 ​ The Company’s accrued expenses and other current liabilities consist primarily of employee incentive compensation plans. The Company accrues over the course of the year the annual discretionary bonuses earned by employees during the year but paid in the following year. Accrued compensation includes bonuses due to employees of $0 and $3.6 million as of December 31, 2021 and 2020, respectively.

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt
Debt	Note 6 Debt As of December 31, 2020, the Company had an outstanding term loan with a principal balance of $100.0 million with Silicon Valley Bank. The interest rate of the term loan as of December 31, 2020 was 5.25% and interest was payable monthly. Under the provisions of the term loan agreement, the Company was required to begin making quarterly principal repayments of $1.25 million commencing on September 30, 2021. Issuance costs associated with the term loan were capitalized and included in other assets on the accompanying consolidated balance sheets. As of December 31, 2020, unamortized debt issuance costs were approximately $1.4 million. On October 25, 2021, the Company used net offering proceeds from the IPO to repay the $98.8 million aggregate principal amount of the term loan. The Company recognized a loss on extinguishment of debt of approximately $1.2 million within Other income (expense) on the accompanying consolidated statements of operations. The Company also has a revolving debt facility with Silicon Valley Bank. The Company did not have any borrowings of the revolving debt outstanding as of December 31, 2021 and 2020. As of December 31, 2021 and 2020, the available unused commitment of the revolving debt was $5.0 million and $4.8 million, respectively. As of December 31, 2021 and 2020, the Company was contingently obligated for a letter of credit in the amount of $0.2 million which bears interest at an annual rate of 2%. ​ The following table details the components of the Company’s debt obligations as of December 31, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ December 31, ​ 2021 2020 Term loan ​ $ — ​ $ 100,000 Less unamortized discount and issuance costs ​ — ​ (1,437) Term loan, net ​ — ​ 98,563 Less current portion ​ — ​ (2,500) Long-term debt, net of unamortized discount and issuance costs ​ $ — ​ $ 96,063 ​

Operating Leases and Service Ag

Operating Leases and Service Agreements	12 Months Ended
	Dec. 31, 2021
Operating Leases and Service Agreements
Operating Leases and Service Agreements	Note 7 Operating Leases and Service Agreements Operating Leases The Company leases office space in various locations under operating lease agreements in the normal course of business, which expire at various dates through 2025. Certain operating leases are secured with cash security deposits or letters of credit. Service Agreements The Company has service agreements for the use of data processing facilities. These service agreements expire at various dates through 2023. Monthly base payments as of December 31, 2021 range from $6 thousand to $16 thousand. Future aggregate minimum rental payments under the noncancelable operating leases and service agreements noted above, excluding the Company’s share of real estate taxes and other operating costs, are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Service ​ ​ Years Ending December 31, ​ Operating Leases ​ Agreements ​ Total 2022 ​ $ 4,384 ​ $ 470 ​ $ 4,854 2023 ​ 3,291 ​ 19 ​ 3,310 2024 ​ 2,385 ​ — ​ 2,385 2025 ​ 901 ​ — ​ 901 Total ​ $ 10,961 ​ $ 489 ​ $ 11,450 ​ Total expense related to these lease agreements was $3.9 million, $3.7 million and $2.5 million for the years ended December 31, 2021, 2020 and 2019, respectively and is included in Cost of revenues and Operating expenses. Total expense related to the service agreements was $1.1 million, $841 thousand and $425 thousand for the years ended December 31, 2021, 2020 and 2019, respectively and is included in Cost of revenues.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies
Commitments and Contingencies	Note 8 Commitments and Contingencies The Company records accruals for contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated based on historical claim activity and loss development factors. There can be no assurance there will not be an increase in the scope of these matters or that any future or pending lawsuits, claims, proceedings, or investigations will not be material. Prior to the IPO, the Company had an agreement with an employee whereby the employee was entitled to receive a percentage of the Company's net profits each year, calculated based on Units held by the employee as a percent of the total number of outstanding Units of the Company (the "Applicable Percentage"). The calculation for 2021 and 2020 equaled 2.0% of net profits. The Company had accrued $347 thousand and $128 thousand as of December 31, 2021 and 2020, respectively, recorded in Accrued expenses and other current liabilities in the Company's consolidated balance sheets. The Company had an additional agreement with this employee under which the employee was entitled to receive a cash payment (the “Buy-Out”) of the Applicable Percentage of (i) in the case of termination, the value of the Company based on the then-most recent valuation ascribed to the Company in an equity financing transaction or (ii) in the case of a sale of the Company, the consideration paid in such transaction. As of December 31, 2020, the Company did not record a liability as the amounts were not probable or estimable. In connection with the Reorganization Transactions (as defined elsewhere in this report), the Company and the employee terminated the agreements through which the employee was entitled to receive an Applicable Percentage of net profits and the Buy-Out in exchange for the right to receive 2,047,064 shares of Class A common stock. These shares will be issued to the employee between the first and second anniversaries of the IPO effectiveness date (see Note 10).

Preferred Units, Stockholders'

Preferred Units, Stockholders' Equity and Members' Deficit	12 Months Ended
	Dec. 31, 2021
Preferred Units, Stockholders' Equity and Members' Deficit
Preferred Units, Stockholders' Equity and Members' Deficit	Note 9 Preferred Units, Stockholders’ Equity and Members’ Deficit Prior to the Reorganization Transactions, Enfusion Ltd. LLC was organized as a limited liability company owned by its members, each of whose membership interests consisted of an equal number of: (i) “Economic Units”, which represented a Member’s economic interest in Enfusion Ltd. LLC; and (ii) “Participation Units”, which represented a Member’s right to participate (vote) in the affairs of Enfusion Ltd. LLC. As a limited liability company, the Enfusion Ltd. LLC issued more than one class of Units. The Class A Units were considered to be Members’ Equity, whereas all of the other Unit classes were considered to be Preferred Units because of provisions in the Company’s former Operating Agreement that conferred certain rights and privileges to the members owning these Units, such as voting rights, redemption rights and liquidation preferences. Holders of the Class C-1, C-2 and D Preferred Units had the option to require the Company to redeem their Units. In accordance with the guidance in ASC 480, Distinguishing Liabilities from Equity The number of Units outstanding by Unit class, the percentage of the Company collectively owned by each Unit class, and the carrying values of these Units in the Company’s consolidated balance sheets as of December 31, 2021 and 2020 are summarized in the following table (in thousands except unit amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ Ownership Carrying ​ Ownership Carrying Unit Class Units ​ Percentage ​ Value ​ Units ​ Percentage ​ Value Preferred Units: ​ ​ Class C-1 Units — ​ — ​ ​ — ​ 28.777 28.28% ​ $ 6,434 Class C-2 Units — ​ — ​ ​ — ​ 12.219 12.01% ​ 44,863 Class D Units — ​ — ​ ​ — ​ 12.778 12.56% ​ 114,218 Total Preferred Units ​ ​ ​ ​ ​ ​ ​ 53.774 52.85% ​ 165,515 Members’ equity (deficit): ​ ​ ​ ​ ​ ​ ​ ​ Class A Units — ​ — ​ ​ — ​ 47.968 47.15% ​ (233,347) Total Preferred Units and Members’ equity (deficit) — — ​ $ — ​ 101.742 100.00% ​ $ (67,832) ​ In connection with the Reorganization Transactions, the Amended and Restated Operating Agreement of Enfusion Ltd. LLC (the “LLC Operating Agreement”) was amended and restated to, among other things, modify its capital structure by reclassifying each of the outstanding Class A Units and C-1, C-2 and D Preferred Units into a new class of LLC interests (or “Common Units”) through a stock split on a 1,000,000 to 1 basis. The number of Common Units outstanding following the Reorganization Transaction reflect the 1,000,000 to 1 stock split. Pursuant to the adoption of the LLC Operating Agreement, Enfusion US 1, Inc., a newly-formed wholly owned subsidiary of Enfusion, Inc., was appointed the sole managing member of Enfusion Ltd. LLC. Amendment and Restatement of Certificate of Incorporation The certificate of incorporation of Enfusion, Inc. provides for 1,000,000,000 authorized shares of Class A common stock, 150,000,000 authorized shares of Class B common stock and 100,000,000 shares of preferred stock. ​ Each share of our Class A common stock is entitled to one vote per share and is not convertible into any other shares of our capital stock. Holders of shares of our Class A common stock are entitled to receive dividends when, as and if declared by our board of directors. Upon our liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors, and subject to the rights of the holders of one or more outstanding series of preferred stock, as applicable, having liquidation preferences, the holders of shares of our Class A common stock will be entitled to receive pro rata our remaining assets available for distribution. Each share of our Class B common stock is entitled to one vote per share and is not convertible or exchangeable for a share of Class A common stock or any other security. Holders of our Class B common stock do not have any right to receive dividends or to receive a distribution upon a liquidation, dissolution or winding up of Enfusion, Inc. ​ Preferred Stock Our board of directors have the authority, without further action by our stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. As of December 31, 2021, the Company has not issued any shares of preferred stock nor has our board of directors established the rights and privileges related to any series of preferred stock.

Management Incentive Plan and S

Management Incentive Plan and Stock-based compensation	12 Months Ended
	Dec. 31, 2021
Management Incentive Plan and Stock-based compensation
Management Incentive Plan and Stock-based compensation	Note 10 Management Incentive Plan and Stock-Based Compensation Prior to the IPO, Enfusion Ltd. LLC had a Change in Control Bonus Plan (the “Pre-IPO Plan”) for certain members of management (“Plan Participants”) that provided for the payment of a cash bonus based on a specified number of Management Incentive Award Units (“Award Units”) in the event of a change in control (“CiC”) transaction (i.e., a liquidity event), as defined by the LLC Operating Agreement. Of the one million Award Units authorized under the Pre-IPO Plan, 22.941 were issued ​ As of December 31, 2020, Enfusion Ltd. LLC had not recorded a liability for payments under the Pre-IPO Plan as the timing of any future CiC transaction or amount of Award Units to be paid to Plan Participants was not probable or estimable. Prior to the IPO, Enfusion Ltd. LLC had not recognized any stock compensation expense related to Award Units granted under the Pre-IPO Plan. ​ In anticipation of the Company’s IPO, in October 2021 the Company's board of managers elected to terminate the Pre-IPO Plan (and all Award Units issued thereunder) upon effectiveness of the registration statement for the IPO (the “IPO effectiveness date”). Holders of Award Units that were still employed as of the IPO date were granted one or more of the following: ​ ● The right to vested shares of Class A common stock that will be issued to Plan Participants between the first and second anniversaries of the IPO effectiveness date. No future service beyond the IPO date is required to receive the shares of Class A common stock. Because there is no ongoing service requirement associated with these awards, the Company recognized stock compensation expense for these awards on the IPO effectiveness date. The amount of stock compensation expense recognized for these awards was $237.3 million, which is equal to the fair value of the shares of Class A common stock, after applying a discount for lack of marketability due to the post-vesting restriction. ​ ● Shares of Class A common stock that will vest within one year of the IPO date due to continued employment requirements, referred to as Contingently Issuable Shares. Such shares will also be issued between the first and second anniversaries of the IPO effectiveness date. Stock compensation expense associated with these awards is recognized by the Company on a straight-line basis over the requisite service period, beginning on the IPO effectiveness date. ​ ● Restricted stock units (“RSUs”) that will vest ratably over a period of up to four years subject to the Plan Participant’s continued employment. Stock compensation expense associated with these awards is recognized by the Company on a straight-line basis over the requisite service period for the entire award, beginning on the IPO effectiveness date. ​ ● RSUs that will vest ratably over a period of up to four years if a specified market capitalization hurdle is achieved, subject to the Plan Participant’s continued employment. The market capitalization hurdle represents a market condition. The Company recognizes stock compensation expense on a straight-line basis over the requisite service period for each tranche of the award, as if the award were in-substance multiple awards. In addition to the shares of Class A common stock and RSUs granted to employees that were Plan Participants in the Pre-IPO Plan, the Company agreed to issue 2,047,064 shares of Class A common stock to an employee in exchange for termination of a profit sharing agreement. These shares will be issued to the employee between the first and second anniversaries of the IPO effectiveness date. The fair value of these shares, after applying a discount for lack of marketability due to the post-vesting restriction, is $31.2 million. This amount was recognized as compensation expense on the IPO effectiveness date. ​ In conjunction with the IPO, the Company established the 2021 Stock Option and Incentive Plan (the “2021 Plan”), which became effective upon the date immediately preceding the IPO effectiveness date. The Company has initially reserved 26,400,000 shares of Class A common stock for the issuance of awards under the 2021 Plan, inclusive of awards granted to Plan Participants of the Pre-IPO Plan. The 2021 Plan provides that the number of shares of Class A common stock reserved and available for issuance under the 2021 Plan will automatically increase on January 1, 2022 and each January 1 thereafter, by 3% of the outstanding number of shares of our Class A and Class B common stock on the immediately preceding December 31, or such lesser number of shares as determined by our compensation committee, or the Annual Increase. The 2021 Plan provides for potential grants of the following awards: (i) stock options, (ii) RSUs, (iii) unrestricted shares, and (iv) stock appreciation rights. Awards granted to date under the 2021 Plan are in the form of RSUs that vest in equal annual installments over four years, subject to the employee’s continued employment. The Company recognizes stock compensation expense for these RSUs on a straight-line basis over the requisite service period for the entire award. ​ The Company measures stock compensation expense for its share-based payment awards at fair value on the grant date. With the exception of RSUs for which vesting is subject to the achievement of a market capitalization hurdle, the fair value of share-based payment awards is determined using the fair market value of the underlying Class A common stock on the date of grant. The Company applies a discount for lack of marketability, estimated using the Finnerty Model, to the fair value of awards with post-vesting restrictions, which includes the vested shares of Class A common stock and the Contingently Issuable Shares of Class A common stock issued on the IPO effectiveness date. ​ For RSUs for which vesting is subject to the achievement of a market capitalization hurdle, the Company determines the fair value of these RSUs using a Monte Carlo simulation. The Monte Carlo simulations used to estimate the fair value include subjective assumptions, including the fair value of the underlying common stock, expected volatility of the price of the Company’s common stock, risk-free interest rate, expected dividend yield of common stock, and the Company’s cost of equity capital. The assumptions used in the Monte Carlo simulations for the RSUs granted on the IPO effectiveness date were as follows: ​ ​ ​ ​ ​ Assumptions for Performance-based shares: October 20, 2021 Fair value of common stock (per share) ​ $ 17.00 Expected volatility ​ ​ 48.20% Risk-free interest rate ​ ​ 1.65% Expected dividend yield ​ ​ 0% Cost of equity capital ​ ​ 11.20% ​ The following summarizes the Company’s share-based payment award activity for the period beginning on the IPO effectiveness date through December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ Number of Shares / RSUs Weighted-Average Fair Value Unvested as of date of IPO ​ — ​ $ — Granted during the period: ​ ​ ​ ​ ​ Vested shares of Class A common stock granted on the IPO effectiveness date ​ 17,582,780 ​ ​ — Contingently issuable shares of Class A common stock granted on the IPO effectiveness date ​ 1,725,708 ​ ​ — RSUs granted to Plan Participants in the Pre-IPO Plan ​ 2,260,168 ​ ​ — RSUs granted to new grantees under the 2021 Plan ​ 644,626 ​ ​ — Total granted during the period ​ 22,213,282 ​ ​ 15.53 Forfeited during the period ​ (35,139) ​ ​ 16.85 Shares redeemed for satisfaction of tax obligations ​ (621,510) ​ ​ 15.27 Outstanding as of December 31, 2021 ​ 21,556,633 ​ ​ 15.57 Vested as of December 31, 2021 ​ 16,961,270 ​ ​ 15.27 Unvested as of December 31, 2021 ​ 4,595,363 ​ $ 16.46 ​ Of the 2,260,168 RSUs granted to Plan Participants in the Pre-IPO Plan, 94,116 of the RSUs are subject to vest based on the achievement of a market capitalization hurdle, which represents a market condition. The remaining 2,166,052 RSUs are subject to vest only based on a service condition. ​ The Company recognized total stock compensation expense for the year ended December 31, 2021 of $289.8 million, of which $268.5 million relates to the vested shares of Class A common stock issued on the IPO effectiveness date. In connection with obligations to issue Class A common stock to former holders of Award Units under our former Change in Control Bonus Plan, the Company paid approximately $15.1 million of tax withholding obligations for federal payroll taxes. Of that amount, approximately $10.6 million related to employee payroll tax withholdings and has accordingly been recorded as a reduction to Additional Paid-In Capital. ​ ​ ​ ​ ​ (in thousands) Year Ended December 31, 2021 Cost of revenues ​ $ 377 General and administrative ​ ​ 112,829 Sales and marketing ​ ​ 36,312 Technology and development ​ ​ 140,285 Total stock compensation expense ​ $ 289,803 Total unrecognized stock compensation expense related to unvested RSUs and Contingently Issuable Shares of Class A stock was $54.2 million as of December 31, 2021, which is expected to be recognized over a weighted-average period of 2 years. ​ In connection with the IPO, we also adopted the 2021 Employee Stock Purchase Plan (“2021 ESPP”). The 2021 ESPP initially reserves and authorizes the issuance of up to a total of 150,000 shares of Class A common stock to participating employees. The 2021 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2022 and each January 1 thereafter through January 1, 2031, by the lesser of (i) 1% of the outstanding number of shares of our Class A common stock and Class B common stock on the immediately preceding December 31 or (ii) such lesser number of shares of Class A common stock as determined by the administrator of the 2021 ESPP. ​ Under the 2021 ESPP, eligible employees may be granted options to purchase shares of Class A common stock at the lower of 85% of the fair market value of the stock at the time of grant or 85% of the fair market value at the time of exercise. As of December 31, 2021, no options were granted to employees.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2021
Employee Benefit Plans
Employee Benefit Plans	Note 11 Employee Benefit Plans The Company sponsors a 401(k) Plan that covers substantially all full-time United States employees who meet eligibility requirements. The Company makes matching contributions equal to 50% of the wages that are deferred by employees, and the matching contribution is capped at 3% of wages. The Company made contributions of $452 thousand, $345 thousand, and $241 thousand for the years ended December 31, 2021, 2020 and 2019, respectively. The Company also sponsors various other benefit plans for its employees of certain international subsidiaries. The Company’s contributions to these plans are immaterial for the periods presented.

Net Income (Loss) Per Class A C

Net Income (Loss) Per Class A Common Share	12 Months Ended
	Dec. 31, 2021
Net Income (Loss) Per Class A Common Share
Net Income (Loss) Per Class A Common Share	Note 12 Net Income (Loss) Per Class A Common Share ​ Basic loss per share is computed by dividing net loss attributable to Enfusion, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. Prior to the IPO, the Enfusion, LLC membership structure included Common Units and multiple classes of Preferred Units. The Company analyzed the calculation of earnings per unit for periods prior to the IPO using the two-class method and determined that it resulted in values that would not be meaningful to the users of these Consolidated Financial Statements. Therefore, earnings per share information has not been presented for periods prior to the IPO on October 20, 2021. The basic and diluted earnings per share represent only the period from October 21, 2021 to December 31, 2021. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows: ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, (in thousands, except per share amounts) ​ 2021 Numerator: ​ ​ ​ Net loss ​ $ (282,242) Less: Net income attributable to Enfusion, Inc. prior to the IPO ​ ​ (12,892) Less: Net loss attributable to non-controlling interests subsequent to the IPO ​ ​ 123,925 Net loss attributable to Enfusion, Inc. ​ ​ (171,209) Adjustment to income (loss) attributable to common stockholders ​ ​ (16,580) Numerator for Basic Earnings per Share ​ $ (187,789) Denominator: ​ ​ ​ Weighted-average shares of Class A common stock outstanding ​ ​ 65,583 Vested shares of Class A common stock ​ ​ 17,462 Weighted-average shares of Class A common stock outstanding--basic ​ ​ 83,045 Net loss per share of Class A common stock--basic and diluted ​ $ (2.26) ​ The following number of potentially dilutive shares were excluded from the calculation of diluted loss per share because the effect of including such potentially dilutive shares would have been antidilutive: ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, (in thousands) ​ 2021 Class B common stock ​ ​ 47,471 Contingently issuable shares of Class A common stock ​ ​ 1,726 Restricted stock units ​ ​ 2,905 ​ ​ ​ 52,102 ​ Shares of Class B common stock do not share in earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been presented. Shares of Class B common stock are, however, considered potentially dilutive shares of Class A common stock. After evaluating the potential dilutive effect under both the treasury stock method and if-converted method, shares of Class B common stock were determined to be anti-dilutive and have therefore been excluded from the computation of diluted earnings per share of Class A common stock.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Taxes
Income Taxes	​ Note 13 Income Taxes ​ The Company is taxed as a corporation for income tax purposes and is subject to federal, state, and local taxes on the income allocated to it from Enfusion Ltd. LLC based upon the Company’s economic interest in Enfusion Ltd. LLC. The Company is the sole managing member of Enfusion Ltd. LLC and, as a result, consolidates the financial results of Enfusion Ltd. LLC. ​ Enfusion Ltd. LLC. is a limited liability company taxed as a partnership for income tax purposes. Enfusion Ltd. LLC does not pay any federal income taxes, as income or loss is included in the tax returns of the individual members. Additionally, certain wholly-owned entities taxed as corporations are subject to federal, state, and foreign income taxes in the jurisdictions in which they operate, and accruals for such taxes are included in the Consolidated Financial Statements. For periods prior to the IPO, the Company’s taxes represent those of Enfusion Ltd. LLC. ​ The components of income (loss) before income taxes were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 2019 U.S. ​ $ (279,990) ​ $ 3,130 ​ $ 12,231 Foreign ​ ​ (1,673) ​ 1,364 ​ 911 Total ​ $ (281,663) ​ $ 4,494 ​ $ 13,142 ​ The income before income taxes above includes the pre- and post-IPO periods during the year ended December 31, 2021. Prior to the IPO the Company, through its subsidiary, Enfusion Ltd. LLC, was structured as a partnership and therefore, was primarily subject to foreign income taxes and generally not subject to U.S. income taxes. As a result of the Reorganization Transactions, the Company is now taxed as a corporation and subject to U.S. federal, state, local and foreign taxes. Significant components of income tax expense (benefit) were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 2019 Current ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Federal ​ $ - ​ $ - ​ $ - State & Local ​ ​ - ​ ​ - ​ ​ - Foreign ​ ​ 228 ​ ​ 433 ​ ​ 486 Total Current Income Tax Expense ​ ​ 228 ​ ​ 433 ​ ​ 486 Deferred ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Federal ​ ​ - ​ ​ - ​ ​ - State & Local ​ ​ - ​ ​ - ​ ​ - Foreign ​ ​ 351 ​ ​ - ​ ​ - Total Deferred Income Tax (Benefit) Expense ​ ​ 351 ​ ​ - ​ ​ - Total ​ $ 579 ​ $ 433 ​ $ 486 A reconciliation of income taxes computed at the U.S. federal statutory income tax rate of 21% to our income tax (expense) benefit was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 2019 ​ At U.S. Federal statutory tax rate ​ ​ 21.00 % ​ 21.00 % ​ 21.00 % State Tax, Net of Federal Benefit ​ ​ 4.28 % ​ - % ​ - % Noncontrolling Interest ​ ​ (9.20) % ​ - % ​ - % Foreign Branch Taxes ​ ​ (0.28) % ​ 9.64 % ​ 3.70 % Equity Based Compensation ​ ​ (2.49) % ​ - % ​ ​ % Foreign Rate Differential ​ ​ 0.04 % ​ (1.14) % ​ (0.42) % Valuation Allowance ​ ​ (14.51) % ​ - % ​ - % Pass-through Loss (Income) ​ ​ 0.91 % ​ (19.86) % ​ (20.58) % Other ​ ​ 0.04 % ​ - % ​ - % Total ​ ​ (0.21) % ​ 9.64 % ​ 3.70 % ​ The Company’s effective tax rate for the years ended December 31, 2021, 2020, and 2019 was (0.21)%, 9.64%, and 3.70%, respectively. The most significant items impacting the effective tax rate are explained below. ​ Pass-through Loss (Income) Prior to the Reorganization Transactions, Enfusion Ltd. LLC was the reporting entity, which is treated as a flow-through entity for U.S. tax purposes. The income or losses generated are generally not taxed at the Enfusion Ltd. LLC level and instead flow through to its various members. The U.S. federal tax impact of the pre-tax book income attributable to Enfusion Ltd. LLC prior to the completion of the IPO was $2.6 million, $0.9 million, and $2.7 million for the years ended December 31, 2021, 2020 and 2019. ​ Noncontrolling Interest ​ The Company’s sole material asset is a financial interest in Enfusion Ltd. LLC. While the Company consolidates Enfusion Ltd. LLC for financial reporting purposes, the Company will only be taxed on (benefit from) its share of earnings (losses) of Enfusion Ltd. LLC not attributed to the noncontrolling interest holders. Since noncontrolling interest holders will continue to bear (benefit from) their share of income tax expense (benefit) on its allocable earnings (losses) of Enfusion Ltd. LLC, that share of income tax expense (benefit) is not reported by the Company in its consolidated financial statements. The U.S. federal tax benefit not attributable to the Company for the year ended December 31, 2021 was $25.9 million. ​ Equity-Based Compensation ​ As a result of the Reorganization Transactions, a significant portion of the Company’s certain equity-based compensation expenses will be allocated to the noncontrolling interest holders and therefore will not be deductible to the Company. The remaining portion of these expenses will be subject to the tax deduction limits as established by the U.S. tax law in respect of the executive compensation. The U.S. federal tax impact of the non-deductible equity-based compensation for the year ended December 31, 2021 was $2.5 million. ​ Valuation Allowance ​ The Company’s net deferred tax benefit of $40.8 million for the year ended December 31, 2021 was fully offset by the valuation allowance recorded in the consolidated statement of operations. ​ Foreign Branch Taxes ​ The Company has foreign operations that are treated as branches for U.S. tax purposes and are also subject to income taxes in those foreign jurisdictions. For the years ending December 31, 2021, 2020 and 2019 the Company recorded $0.6 million, $0.4 million, and $0.5 million in foreign income taxes related to the pre-tax income of its branches. ​ The components of deferred tax assets and liabilities are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Deferred Tax Assets ​ ​ ​ ​ ​ ​ Investment in Enfusion Ltd. LLC ​ $ 80,124 ​ $ - Equity Based Compensation ​ ​ 38,362 ​ ​ - Net Operating Losses ​ ​ 5,475 ​ ​ - Other ​ ​ 565 ​ ​ - Total Deferred Tax Assets ​ ​ 124,526 ​ ​ - Valuation Allowance ​ ​ (124,526) ​ ​ - Total Deferred Tax Assets Net of Valuation Allowance ​ ​ - ​ ​ - Deferred tax liabilities ​ ​ - ​ ​ - Property, Plant, and Equipment ​ ​ (351) ​ ​ - Total Deferred Tax Liabilities ​ ​ (351) ​ ​ - Net Deferred Tax Liabilities ​ $ (351) ​ $ - ​ The Company’s deferred tax assets are comprised primarily of basis difference in Enfusion Ltd. LLC, equity-based compensation expense and tax attribute carryforwards. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income sufficient to utilize the deferred tax assets on the Company’s income tax returns. Management determined that its deferred tax assets are not more likely than not going to be realized due to the Company’s three-year cumulative loss position and the generation of future taxable income is uncertain. Considering this and other factors, the Company recognized a full valuation allowance of $124.5 million as of December 31, 2021. The total amount of valuation allowance recorded to additional paid-in capital as a result of the Reorganization Transactions, IPO and the Company’s purchase of additional Enfusion Ltd. LLC units during the year ended December 31, 2021 was $83.1 million. ​ As of December 31, 2021, the Company had U.S. net operating losses of $18.4 million which can be carried forward indefinitely. ​ As of December 31, 2021, the Company is not indefinitely reinvested on undistributed earnings from its foreign operations. Due to the Company's structure, the foreign operations do not qualify for the indefinite reinvestment exceptions under ASC 740-30 as the earnings from the foreign operations are subject to U.S. taxation. However, the exception may still apply to foreign withholding taxes due to dividend distributions of earnings from the Company's foreign affiliates. The Company has no plans to make distributions from its foreign operations in the future and, therefore, a deferred tax liability has not been recognized. A determination of the unrecognized deferred taxes is not practicable. ​ A summary of the Company’s uncertain tax positions is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 2019 Beginning balance ​ $ - ​ $ - ​ $ - Increases for tax positions related to the current year ​ ​ 30 ​ ​ - ​ ​ - Increases (decreases) for tax positions of prior years ​ ​ 89 ​ ​ - ​ ​ - Ending balance ​ $ 119 ​ $ - ​ $ - Interest and penalties ​ $ 65 ​ $ - ​ $ - ​ Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. As of December 31, 2021, we accrued $65 thousand of interest and penalties. There were no interest expense and penalties accrued for the years ended December 31, 2020 and 2019. ​ We can be subject to routine income tax examinations in the U.S. federal, state, local and foreign jurisdictions for tax years 2018 and forward. At December 31, 2021, the Company is not under income tax audit in any of the jurisdictions in which it operates. ​ CARES Act On March 27, 2020, the President signed the CARES Act to provide emergency relief related to the COVID-19 pandemic. The CARES Act contains federal income tax provisions which, among other things; (i) increases the amount of interest expense that businesses are allowed to deduct by increasing the adjusted taxable income limitation from 30% to 50% for tax years that begin in 2019 and 2020; (ii) permits businesses to carry back to each of the five tax years net operating losses arising from tax years beginning after December 31, 2017 and before January 1, 2021; and (iii) temporarily removes the 80% limitation on net operating losses until tax years beginning after 2020. The CARES Act provisions do not have a material impact on the Company’s financial statements. ​ Tax Receivable Agreement ​ The Company expects to obtain an increase in its share of the tax basis in the net assets of Enfusion Ltd. LLC when Enfusion Ltd. LLC units are redeemed from or exchanged by the Pre-IPO common unit holders. The Company intends to treat any redemptions and exchanges of Enfusion Ltd. LLC units as direct purchases of Enfusion Ltd. LLC units for U.S. income tax purposes. These increases in tax basis may reduce the amounts that the Company would otherwise pay in the future to U.S. federal and state tax authorities. They may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. ​ In connection with the IPO, the Company entered into the Tax Receivable Agreement with Enfusion Ltd. LLC, the Continuing Equity Owners and the Blocker Shareholders that will provide for the payment by the Company to the Continuing Equity Owners and the Blocker Shareholders of 85% of the amount of tax benefits, if any, that the Company actually realizes (or in some circumstances is deemed to realize) as a result of (1) the Company’s allocable share of existing tax basis acquired in connection with the Reorganization Transactions (including the Blocker Company’s share of existing tax basis) and increases to such allocable share of existing tax basis; (2) increases in tax basis resulting from (a) the Company’s purchase of LLC Interests directly from Enfusion Ltd. LLC and the partial redemption of LLC Interests by Enfusion Ltd. LLC, (b) future redemptions or exchanges (or deemed exchanges in certain circumstances) of LLC Interests for Class A common stock or cash, and (c) certain distributions (or deemed distributions) by Enfusion Ltd. LLC; and (3) certain additional tax benefits arising from payments made under the Tax Receivable Agreement. The Company may benefit from the remaining 15% of any tax benefits that the Company actually realizes. ​ Following the Reorganization Transactions and IPO in the year ended December 31, 2021, the Company purchased an aggregate of 5,526,607 Enfusion Ltd. LLC units in connection with the exchange of those units by the Pre-IPO common unit holders and retirement of six Class B common shares, which resulted in an increase of $87.8 million in the tax basis of the net assets of Enfusion Ltd. LLC and would be subject to the provisions of the Tax Receivable Agreement. ​ As of December 31, 2021, the Company has not recorded a liability under the Tax Receivable Agreement related to the tax benefits originating from the Reorganization Transactions, IPO and subsequent purchase of Enfusion Ltd. LLC units during the year ended December 31, 2021 as it is not probable that the Company will realize such tax benefits. To the extent we had determined that we would have been able to realize the tax benefits associated with the basis adjustments, we would have recorded a liability under the Tax Receivable Agreement of $74.7 million as of December 31, 2021. ​ The amounts payable under the Tax Receivable Agreement will vary depending upon a number of factors, including the amount, character, and timing of the taxable income of the Company in the future. Should the Company determine that the Tax Receivable Agreement liability be considered probable at a future date based on new information, any changes will be recorded within income tax expense (benefit) at that time.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions
Related Party Transactions	Note 14 Related Party Transactions Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial or operating decisions. Since transactions with related parties may raise potential or actual conflicts of interest between the related party and the Company, upon the completion of the IPO the Company implemented a related party transaction policy that requires related party transactions to be reviewed and approved by its nominating and corporate governance committee. The Company used the proceeds (net of underwriting discounts) from the issuance of 5,526,607 million shares in the IPO ($87.8 million) to purchase an equivalent number of Common Units from the Company’s Pre-IPO Common Unitholders. Concurrent with the completion of the IPO, the Company entered into a Tax Receivable Agreement with certain of its Pre-IPO Owners. On December 24, 2020, Enfusion Ltd. LLC issued and sold an aggregate amount of 7.964 Class D Units to ICONIQ Strategic Partners V, L.P., or ICONIQ, and EF ISP V-B Blocker, Inc., at a purchase price of approximately $11.7 million per Class D Unit, for a total purchase price of approximately $93.5 million. On December 24, 2020, FTV Enfusion Holdings, Inc., which held 32.693 Class C-1 Units and 7.494 Class C-2 Units, exchanged 3.916 Class C-1 Units and 0.898 Class C-2 Units for 4.814 Class D Units. Following the exchange, FTV Enfusion Holdings, Inc. issued 4.814 shares of Class D Units to ICONIQ in exchange for approximately $56.5 million. ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies
Principles of Consolidation	Principles of Consolidation The Reorganization Transactions were accounted for as a reorganization of entities under common control. As a result, the consolidated financial statements of Enfusion, Inc. recognized the assets and liabilities received in the Reorganization Transactions at their historical carrying amounts, as reflected in the historical financial statements of Enfusion Ltd. LLC. Accordingly, the financial statements for periods prior to the IPO and the Reorganization Transactions have been adjusted to combine the previously separate entities for presentation purposes. These statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions are eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and various other assumptions believed to be reasonable. These estimates and assumptions include, but are not limited to, judgments affecting the measurement of the payable to related parties pursuant to the Tax Receivable Agreement, amortization periods, certain assumptions used in the valuation of stock-based compensation, assessment of the allowance for doubtful accounts, and accounting for income taxes and assessment of valuation allowances. Actual results could differ from those estimates. ​ The Company’s results can also be affected by economic, political, legislative, regulatory and legal actions, including but not limited to health epidemics and pandemics and the resulting economic impact, including the impact from the COVID-19 pandemic. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, and government fiscal policies can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities and carries various levels of insurance, the Company could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings.
Segments	Segments Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the CODM. While the Company operates in multiple countries, the Company’s business operates as one operating segment because most of the Company’s service offerings are delivered and supported on a global basis, the Company’s service offerings are deployed in a nearly identical way, and the Company’s CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.
Cash	Cash Cash includes cash in banks, cash on hand, and overnight deposits.
Accounts Receivable	Accounts Receivable Accounts receivable includes billed and unbilled receivables, net of allowance of doubtful accounts. Billed accounts receivable are initially recorded upon the invoicing to clients with payment due within 30 days. Unbilled accounts receivable represent revenue recognized on contracts for which the timing of invoicing to clients differs from the timing of revenue recognition. As of December 31, 2021 and 2020, unbilled accounts receivable was $1.3 million and $349 thousand, respectively. The unbilled accounts receivable balance is due within one year. The Company maintains an allowance for doubtful accounts at an amount estimated to be sufficient to provide adequate protection against losses resulting from extending credit to its clients. The Company regularly determines the adequacy of the allowance based on its assessment of the collectability of the accounts receivable by considering the age of each outstanding invoice, the collection history of each client, and an evaluation of current expected risk of credit loss of any clients with known financial difficulties. The Company assesses collectability by reviewing accounts receivable on an aggregated basis where similar characteristics exist and on an individual basis for specific clients with historical collectability issues or known financial difficulties. Increases to the allowance are recognized as a charge to doubtful accounts included in General and administrative expenses in the consolidated statement of operations. Accounts receivable deemed uncollectible are charged against the allowance for doubtful accounts when identified. The Company's allowances are as follows (in thousands): ​ ​ ​ ​ ​ Balance at December 31, 2019 ​ $ 95 Charges to the provision ​ ​ 1,010 Accounts written off, net of recoveries ​ (507) Balance at December 31, 2020 ​ 598 Charges to the provision ​ 1,450 Accounts written off, net of recoveries ​ (1,257) Balance at December 31, 2021 ​ $ 791
Property and Equipment, Net	Property and Equipment, Net Property and equipment is stated at historical cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the individual assets, except for leasehold improvements, which are depreciated over the shorter of the estimated useful life of the asset or the underlying lease term. Also included in property and equipment are capitalized costs of software developed for internal use. The useful lives of property and equipment are as follows: ​ ​ ​ Property and Equipment Asset Type Estimated Useful Lives Software development costs 3 years Computers and equipment 5 years Furniture and fixtures 5 years Leasehold improvements Shorter of estimated economic useful life or remaining lease term ​ Maintenance and repairs are expensed as incurred. Upon retirement or disposition, the cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is included in operating income.
Software Development Costs	Software Development Costs Capitalized software costs consist of costs to purchase software to be used within the Company and costs to develop software internally. Capitalization of purchased or internally developed software occurs during the application development stage and consists of design, coding and testing. Amortization of software development costs is calculated using the straight-line method over the estimated useful lives of the software, which is generally three years. Capitalized software development costs are recorded within property and equipment, net of accumulated amortization, within the consolidated balance sheets. Amortization expense is included in Cost of revenues – platform subscription services in the consolidated statements of operations.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates the carrying value of long-lived assets, including identifiable intangibles, in accordance with the accounting standard for impairment or disposal of long-lived assets, which requires recognition of impairment of long-lived assets in the event that circumstances indicate impairment may have occurred and when the net carrying value of such assets exceeds the future undiscounted cash flows attributed to such assets. The Company assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. No impairment of long-lived assets occurred during the years ended December 31, 2021, 2020 and 2019.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the exit price) in an orderly transaction between market participants at the measurement date. Accounting standards establish a hierarchal framework, which prioritizes and ranks the level of market price observability used in measuring assets and liabilities at fair value. Market price observability is impacted by a number of factors, including the type of investment and the characteristics specific to the investment. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from independent sources. Unobservable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on the best information available. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories: Level 1 Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 Inputs are inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and Level 3 Inputs are unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. As of December 31, 2020, the carrying value of the Company’s long-term debt approximated its fair value, which represents a Level 2 fair value measurement. The carrying amount of the Company’s other financial instruments, including accounts receivable and accounts payable, approximate fair value due to their short-term nature.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification 606 (“ASC 606”), Revenue Recognition Historically, platform subscription contracts have typically had a one-year term and were cancellable with 30 days’ notice, though our more recent contracts have typically been for multi-year terms without cancellation for convenience. Clients are invoiced each month for the services provided in accordance with the stated terms of their service contracts. Fees for partial term service contracts are prorated, as applicable. Payment of fees are due from clients within 30 days of the invoice date. The Company does not provide financing to clients. The Company determines revenue recognition through the following five-step framework: ● Identification of the contract, or contracts, with a client; ● Identification of the performance obligation in the contract; ● Determination of transaction price; ● Allocation of the transaction price to the performance obligations in the contract; and ● Recognition of revenue when, or as, performance obligations are satisfied. Platform subscription revenues Platform subscription revenues consist primarily of fees for providing clients with access to the Company’s cloud-based platform. Platform subscription clients do not have the right to take possession of the platform’s software, and do not have any general return rights. Platform subscription revenues are generally recognized ratably over the period of contractually enforceable rights and obligations, beginning on the date that the client gains access to the platform. Installment payments are invoiced at the end of each calendar month during the subscription term. Managed services revenues Managed services revenues primarily consist of client-selected middle and back-office services provided on our clients’ behalf using the Company’s platform. Revenue is recognized monthly as the managed services are performed, with invoicing occurring at the end of the calendar month. Other revenues Other revenues consists of non-subscription-based revenues, such as software enhancements developed for individual, sponsoring clients, but received by all clients, and data conversion and services that integrate a client’s historical data into our solution. We recognize revenues monthly as these services are performed with invoicing occurring at the end of each month. Service contracts with multiple performance obligations Our service contracts with clients can include multiple performance obligations. For these contracts, we account for individual performance obligations separately if they are distinct. However, all distinct performance obligations within a contract are satisfied over a similar period of time with the same measure of progress. Accordingly, each distinct performance obligation within a contract has the same pattern of revenue recognition. We have determined that implementation services are not distinct from the ongoing platform subscription services due to the highly specialized knowledge required to execute on our solution. Such services are recognized with the platform subscription services revenue over time. Disaggregation of revenue The Company’s total revenues by geographic region, based on the client’s physical location is presented in the following table: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 Geographic Region Amount Percent Amount Percent ​ Amount Percent Americas* ​ $ 72,994 65.3% ​ $ 54,057 67.9% ​ $ 42,158 71.4% Europe, Middle East and Africa (EMEA) ​ 13,491 12.1% ​ 8,748 11.0% ​ 6,727 11.4% Asia Pacific (APAC) ​ 25,215 22.6% ​ 16,760 21.1% ​ 10,142 17.2% Total revenues ​ $ 111,700 100.0% ​ $ 79,565 100.0% ​ $ 59,027 100.0% ​ * Includes revenues in the United States (country of domicile) of $71.9 million, $53.0 million and $41.4 million for the years ended December 31, 2021, 2020 and 2019, respectively. Remaining performance obligations The Company has elected not to disclose the amount of the transaction price allocated to remaining performance obligations for contracts with an initial term of one year or less, which is the majority of the Company’s contracts. For the Company’s contracts that exceed one year and do not include a termination for convenience clause, the amount of the transaction price allocated to remaining performance obligations as of December 31, 2021 was $23.4 million. The Company expects to recognize this amount over the next one Deferred commissions The Company pays sales commissions for initial contracts and expansions of existing contracts with customers. These commissions earned by certain of our sales force are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions paid where the amortization period is one year or less are expensed as incurred. All other sales commissions are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be three years. We determined the period of benefit by taking into consideration our standard contract terms and conditions, rate of technological change, and other factors. Amortization expense is included in sales and marketing expense in the accompanying consolidated statements of operations. The balance of deferred commissions as of December 31, 2021 was $1.7 million and is included in Other assets on the Consolidated Balance Sheets. The amount of amortization expense recognized during the year ended December 31, 2021 was $228 thousand. Deferred commissions and amortization expense were not recorded for the year ended December 31, 2020, as the commissions earned under the prior year commission program were not incremental and recoverable costs of obtaining contracts with customers. Cost of revenues Cost of revenues consists primarily of personnel-related costs associated with the delivery of the Company’s software and services, including base salaries, bonuses, employee benefits and related costs, Additionally, cost of revenues includes amortization of capitalized software development costs, allocated overhead and certain direct data and hosting costs.
Research and Development	Research and Development Research and development expenses consist primarily of employee-related expenses for the Company’s software development. Additional expenses include costs related to the development, maintenance, quality assurance and testing of new technologies, and ongoing refinement of the Company’s existing solutions. Research and development expenses, other than internal-use software costs qualifying for capitalization, including costs associated with preliminary project stage activities, training, maintenance, and all other post-implementation stage activities are expensed as incurred.
Advertising Costs	Advertising Costs The Company expenses advertising costs as incurred. Advertising costs incurred were approximately $1.2 million, $1.3 million and $464 thousand during the years ended December 31, 2021, 2020 and 2019, respectively.
Leases	Leases The Company leases office facilities under operating leases and data centers under service agreements, and accounts for those leases in accordance with ASC 840, Leases
Equity based compensation	Equity-Based Compensation Prior to the IPO, the Company had a Change in Control Bonus Plan (the “Plan”) for certain members of the Company’s management (“Plan Participants”) that provided for the payment of a cash bonus based on a specified number of Management Incentive Award Units (“Award Units”) in the event of a change in control (“CiC”) transaction (i.e., a liquidity event), as defined by the Company’s Operating Agreement. As of December 31, 2020 and December 31, 2019, respectively, the Company did not record a liability for payments under the Plan as the timing of any future CiC transaction or amount of Award Units to be paid to Plan Participants was not probable or estimable. In October 2021, the Company's board of managers elected to terminate the Change in Control Bonus Plan (and all Award Units issued thereunder) upon effectiveness of the registration statement for the IPO. In connection with the IPO, we adopted the 2021 Stock Option and Incentive Plan, or 2021 Plan. The 2021 Plan allows our compensation committee to make incentive awards to our officers, employees, directors and service providers. We also adopted the 2021 Employee Stock Purchase Plan, or 2021 ESPP. The Company measures stock compensation expense for its share-based payment awards at fair value on the grant date. The fair value of share-based payment awards is determined using the fair market value of the underlying Class A common stock on the date of grant. The Company applies a discount for lack of marketability, estimated using the Finnerty Model, to the fair value of awards with post-vesting restrictions, which includes the vested shares of Class A common stock and the contingently issuable shares (the “Contingently Issuable Shares”) of Class A common stock issued on the IPO effectiveness date. For RSUs for which vesting is subject to the achievement of a market capitalization hurdle, the Company determines the fair value of these RSUs using a Monte Carlo simulation. The Monte Carlo simulations used to estimate the fair value include subjective assumptions, including the fair value of the underlying common stock, expected volatility of the price of the Company’s common stock, risk-free interest rate, expected dividend yield of common stock, and the Company’s cost of equity capital. We record forfeitures as they occur. The cost of services received from employees and non-employees in exchange for awards of equity instruments is recognized in the consolidated statement of operations based on the estimated fair value of those awards on the grant date or reporting date, if required to be remeasured, and amortized on a straight-line basis over the requisite service period.
Earnings (loss) per share	Earnings (loss) per share Basic earnings (loss) per share is computed by dividing net earnings (loss) attributable to the Company by the number of weighted average shares of Class A common stock outstanding during the period. Diluted earnings (loss) per share is computed by dividing net earnings (loss) attributable to the Company by the number of weighted-average shares of Class A common stock outstanding during the period after adjusting for the impact of securities that would have a dilutive effect on earnings (loss) per share. See Note 12, Income Loss) Per Class A Common Share All earnings (loss) for the period prior to the IPO were entirely allocable to Enfusion LLC, Ltd. and its historic non-controlling interest. Due to the impact of the Reorganization Transactions, the Company’s capital structure for the pre- and post-IPO periods is not comparable. As a result, the presentation of earnings (loss) per share for the periods prior to the IPO and Organizational Transactions is not meaningful and only earnings (loss) per share for the period subsequent to the IPO and Organizational Transactions is presented herein.
Non-controlling interest	Non-controlling interest Non-controlling interests represent the portion of profit or loss, net assets and comprehensive income of our consolidated subsidiaries that is not allocable to the Company based on our percentage of ownership of such entities.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method, and deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates on deferred tax assets and deferred tax liabilities is recognized in income in the period that includes the enactment date. We recognize deferred tax assets to the extent that it is believed that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations. A valuation allowance is provided if it is determined that it is more likely than not that the deferred tax asset will not be realized. The Company evaluates and accounts for uncertain tax positions using a two-step approach. Recognition (step one) occurs when the Company concludes that a tax position, based solely on its technical merits, is more-likely-than-not to be sustainable upon examination. Measurement (step two) determines the amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. Derecognition of a tax position that was previously recognized would occur when the Company subsequently determines that a tax position no longer meets the more likely-than-not threshold of being sustained. The Company records interest (and penalties where applicable), net of any applicable related income tax benefit, on potential income tax contingencies as a component of Income tax expense in the Consolidated Statements of Operations.
Tax Receivable Agreement (TRA)	Tax Receivable Agreement (TRA) The Company accounts for amounts payable under the TRA in accordance with ASC 450, Contingencies
Concentration of Risk	Concentration of Risk Deposits with Financial Institutions The Company has concentrated its credit risk for cash by maintaining deposits in several financial institutions, which may at times exceed amounts covered by insurance provided by the Federal Deposit Insurance Corporation (“FDIC”). The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk related to cash. Accounts Receivable As of December 31, 2021 and 2020, no individual client represented more than 10% of accounts receivable. For the years ended December 31, 2021, 2020 and 2019, no individual client represented more than 10% of the Company’s total revenues.
Translation of Foreign Currencies	Translation of Foreign Currencies Foreign currency assets and liabilities of the Company’s international subsidiaries are translated using the exchange rates in effect at the balance sheet date. Results from operations are translated using the average exchange rates prevailing throughout the year. The effects of exchange rate fluctuations on translating foreign currency assets and liabilities into U.S. dollars are accumulated as part of the foreign currency translation adjustment in Preferred Units and Members’ Equity (Deficit) in the consolidated balance sheets.
Recently Adopted Pronouncements\Recent Accounting Pronouncements Not Yet Adopted	Recently Adopted Pronouncements In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Softwar Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. Recent Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued ASU 2016-02 , Leases Leases Codification Improvements to Topic 842, Leases Leases In December 2019, the FASB issued ASU 2019-12, Income Taxes Simplifying the Accounting for Income Taxes In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses Measurement of Credit Losses on Financial Instruments

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies
Schedule of accounts receivable allowance for credit loss	​ ​ ​ ​ ​ Balance at December 31, 2019 ​ $ 95 Charges to the provision ​ ​ 1,010 Accounts written off, net of recoveries ​ (507) Balance at December 31, 2020 ​ 598 Charges to the provision ​ 1,450 Accounts written off, net of recoveries ​ (1,257) Balance at December 31, 2021 ​ $ 791
Schedule of property, plant and equipment useful life	​ ​ ​ Property and Equipment Asset Type Estimated Useful Lives Software development costs 3 years Computers and equipment 5 years Furniture and fixtures 5 years Leasehold improvements Shorter of estimated economic useful life or remaining lease term
Schedule of total net revenues by geographic region	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 Geographic Region Amount Percent Amount Percent ​ Amount Percent Americas* ​ $ 72,994 65.3% ​ $ 54,057 67.9% ​ $ 42,158 71.4% Europe, Middle East and Africa (EMEA) ​ 13,491 12.1% ​ 8,748 11.0% ​ 6,727 11.4% Asia Pacific (APAC) ​ 25,215 22.6% ​ 16,760 21.1% ​ 10,142 17.2% Total revenues ​ $ 111,700 100.0% ​ $ 79,565 100.0% ​ $ 59,027 100.0% ​ * Includes revenues in the United States (country of domicile) of $71.9 million, $53.0 million and $41.4 million for the years ended December 31, 2021, 2020 and 2019, respectively.

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Property and Equipment, Net
Schedule of Property and equipment, net	Property and equipment, net consists of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 ​ 2020 Computer equipment and software ​ $ 14,163 ​ $ 8,533 Software development costs ​ 4,866 ​ 2,948 Leasehold improvements ​ 1,947 ​ 1,406 Furniture and fixtures ​ 540 ​ 671 Total property and equipment, cost ​ 21,516 ​ 13,558 Less accumulated depreciation and amortization ​ (8,465) ​ (4,774) Total property and equipment, net ​ $ 13,051 ​ $ 8,784
Schedule of estimated future amortization of capitalized software development costs	Estimated future amortization of capitalized software development costs are as follows (in thousands): ​ ​ ​ ​ Year ending December 31, Amount 2022 ​ $ 1,289 2023 ​ 863 2024 ​ 293 Total ​ $ 2,445

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Accrued Expenses and Other Current Liabilities
Schedule of accrued expenses and other current liabilities	Accrued expenses and other current liabilities consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Accrued compensation ​ $ 3,180 ​ $ 5,261 Accrued expenses ​ 1,182 ​ 1,478 Accrued taxes ​ 1,216 ​ 414 Accrued interest ​ — ​ 218 Current portion of deferred rent ​ — ​ 29 Other current liabilities ​ — ​ 266 Total accrued expenses and other current liabilities ​ $ 5,578 ​ $ 7,666

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt
Schedule of components of debt obligations	​ ​ ​ ​ ​ ​ ​ ​ (in thousands) ​ December 31, ​ 2021 2020 Term loan ​ $ — ​ $ 100,000 Less unamortized discount and issuance costs ​ — ​ (1,437) Term loan, net ​ — ​ 98,563 Less current portion ​ — ​ (2,500) Long-term debt, net of unamortized discount and issuance costs ​ $ — ​ $ 96,063

Operating Leases and Service _2

Operating Leases and Service Agreements (Tables)	12 Months Ended
	Dec. 31, 2021
Operating Leases and Service Agreements
Schedule of future aggregate minimum rental payments	Future aggregate minimum rental payments under the noncancelable operating leases and service agreements noted above, excluding the Company’s share of real estate taxes and other operating costs, are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Service ​ ​ Years Ending December 31, ​ Operating Leases ​ Agreements ​ Total 2022 ​ $ 4,384 ​ $ 470 ​ $ 4,854 2023 ​ 3,291 ​ 19 ​ 3,310 2024 ​ 2,385 ​ — ​ 2,385 2025 ​ 901 ​ — ​ 901 Total ​ $ 10,961 ​ $ 489 ​ $ 11,450

Preferred Units Stockholders' E

Preferred Units Stockholders' Equity and Members' Deficit (Tables)	12 Months Ended
	Dec. 31, 2021
Preferred Units, Stockholders' Equity and Members' Deficit
Schedule of Preferred Units and Members' equity (deficit)	The number of Units outstanding by Unit class, the percentage of the Company collectively owned by each Unit class, and the carrying values of these Units in the Company’s consolidated balance sheets as of December 31, 2021 and 2020 are summarized in the following table (in thousands except unit amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ Ownership Carrying ​ Ownership Carrying Unit Class Units ​ Percentage ​ Value ​ Units ​ Percentage ​ Value Preferred Units: ​ ​ Class C-1 Units — ​ — ​ ​ — ​ 28.777 28.28% ​ $ 6,434 Class C-2 Units — ​ — ​ ​ — ​ 12.219 12.01% ​ 44,863 Class D Units — ​ — ​ ​ — ​ 12.778 12.56% ​ 114,218 Total Preferred Units ​ ​ ​ ​ ​ ​ ​ 53.774 52.85% ​ 165,515 Members’ equity (deficit): ​ ​ ​ ​ ​ ​ ​ ​ Class A Units — ​ — ​ ​ — ​ 47.968 47.15% ​ (233,347) Total Preferred Units and Members’ equity (deficit) — — ​ $ — ​ 101.742 100.00% ​ $ (67,832)

Management Incentive Plan and_2

Management Incentive Plan and Stock-based compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Management Incentive Plan and Stock-based compensation
Schedule of assumptions	​ ​ ​ ​ Assumptions for Performance-based shares: October 20, 2021 Fair value of common stock (per share) ​ $ 17.00 Expected volatility ​ ​ 48.20% Risk-free interest rate ​ ​ 1.65% Expected dividend yield ​ ​ 0% Cost of equity capital ​ ​ 11.20%
Schedule of share-based payment award activity	​ ​ ​ ​ ​ ​ ​ ​ Number of Shares / RSUs Weighted-Average Fair Value Unvested as of date of IPO ​ — ​ $ — Granted during the period: ​ ​ ​ ​ ​ Vested shares of Class A common stock granted on the IPO effectiveness date ​ 17,582,780 ​ ​ — Contingently issuable shares of Class A common stock granted on the IPO effectiveness date ​ 1,725,708 ​ ​ — RSUs granted to Plan Participants in the Pre-IPO Plan ​ 2,260,168 ​ ​ — RSUs granted to new grantees under the 2021 Plan ​ 644,626 ​ ​ — Total granted during the period ​ 22,213,282 ​ ​ 15.53 Forfeited during the period ​ (35,139) ​ ​ 16.85 Shares redeemed for satisfaction of tax obligations ​ (621,510) ​ ​ 15.27 Outstanding as of December 31, 2021 ​ 21,556,633 ​ ​ 15.57 Vested as of December 31, 2021 ​ 16,961,270 ​ ​ 15.27 Unvested as of December 31, 2021 ​ 4,595,363 ​ $ 16.46 ​
Schedule of stock compensation expense	​ ​ ​ ​ (in thousands) Year Ended December 31, 2021 Cost of revenues ​ $ 377 General and administrative ​ ​ 112,829 Sales and marketing ​ ​ 36,312 Technology and development ​ ​ 140,285 Total stock compensation expense ​ $ 289,803

Net Income (Loss) Per Class A_2

Net Income (Loss) Per Class A Common Share (Tables)	12 Months Ended
	Dec. 31, 2021
Net Income (Loss) Per Class A Common Share
Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share	​ ​ ​ ​ ​ ​ ​ Year Ended December 31, (in thousands, except per share amounts) ​ 2021 Numerator: ​ ​ ​ Net loss ​ $ (282,242) Less: Net income attributable to Enfusion, Inc. prior to the IPO ​ ​ (12,892) Less: Net loss attributable to non-controlling interests subsequent to the IPO ​ ​ 123,925 Net loss attributable to Enfusion, Inc. ​ ​ (171,209) Adjustment to income (loss) attributable to common stockholders ​ ​ (16,580) Numerator for Basic Earnings per Share ​ $ (187,789) Denominator: ​ ​ ​ Weighted-average shares of Class A common stock outstanding ​ ​ 65,583 Vested shares of Class A common stock ​ ​ 17,462 Weighted-average shares of Class A common stock outstanding--basic ​ ​ 83,045 Net loss per share of Class A common stock--basic and diluted ​ $ (2.26)
Schedule of effect of dilutive shares antidilutive	​ ​ ​ ​ ​ ​ ​ Year Ended December 31, (in thousands) ​ 2021 Class B common stock ​ ​ 47,471 Contingently issuable shares of Class A common stock ​ ​ 1,726 Restricted stock units ​ ​ 2,905 ​ ​ ​ 52,102

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Taxes
Schedule of components of income (loss) before income taxes	The components of income (loss) before income taxes were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 2019 U.S. ​ $ (279,990) ​ $ 3,130 ​ $ 12,231 Foreign ​ ​ (1,673) ​ 1,364 ​ 911 Total ​ $ (281,663) ​ $ 4,494 ​ $ 13,142
Schedule of components of income tax expense (benefit)	Reorganization Transactions, the Company is now taxed as a corporation and subject to U.S. federal, state, local and foreign taxes. Significant components of income tax expense (benefit) were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 2019 Current ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Federal ​ $ - ​ $ - ​ $ - State & Local ​ ​ - ​ ​ - ​ ​ - Foreign ​ ​ 228 ​ ​ 433 ​ ​ 486 Total Current Income Tax Expense ​ ​ 228 ​ ​ 433 ​ ​ 486 Deferred ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Federal ​ ​ - ​ ​ - ​ ​ - State & Local ​ ​ - ​ ​ - ​ ​ - Foreign ​ ​ 351 ​ ​ - ​ ​ - Total Deferred Income Tax (Benefit) Expense ​ ​ 351 ​ ​ - ​ ​ - Total ​ $ 579 ​ $ 433 ​ $ 486
Schedule of reconciliation of the U.S. statutory income tax rate to our effective income tax rate	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 2019 ​ At U.S. Federal statutory tax rate ​ ​ 21.00 % ​ 21.00 % ​ 21.00 % State Tax, Net of Federal Benefit ​ ​ 4.28 % ​ - % ​ - % Noncontrolling Interest ​ ​ (9.20) % ​ - % ​ - % Foreign Branch Taxes ​ ​ (0.28) % ​ 9.64 % ​ 3.70 % Equity Based Compensation ​ ​ (2.49) % ​ - % ​ ​ % Foreign Rate Differential ​ ​ 0.04 % ​ (1.14) % ​ (0.42) % Valuation Allowance ​ ​ (14.51) % ​ - % ​ - % Pass-through Loss (Income) ​ ​ 0.91 % ​ (19.86) % ​ (20.58) % Other ​ ​ 0.04 % ​ - % ​ - % Total ​ ​ (0.21) % ​ 9.64 % ​ 3.70 %
Schedule of components of deferred tax assets and liabilities	The components of deferred tax assets and liabilities are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Deferred Tax Assets ​ ​ ​ ​ ​ ​ Investment in Enfusion Ltd. LLC ​ $ 80,124 ​ $ - Equity Based Compensation ​ ​ 38,362 ​ ​ - Net Operating Losses ​ ​ 5,475 ​ ​ - Other ​ ​ 565 ​ ​ - Total Deferred Tax Assets ​ ​ 124,526 ​ ​ - Valuation Allowance ​ ​ (124,526) ​ ​ - Total Deferred Tax Assets Net of Valuation Allowance ​ ​ - ​ ​ - Deferred tax liabilities ​ ​ - ​ ​ - Property, Plant, and Equipment ​ ​ (351) ​ ​ - Total Deferred Tax Liabilities ​ ​ (351) ​ ​ - Net Deferred Tax Liabilities ​ $ (351) ​ $ -
Schedule of company's uncertain tax positions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2021 2020 2019 Beginning balance ​ $ - ​ $ - ​ $ - Increases for tax positions related to the current year ​ ​ 30 ​ ​ - ​ ​ - Increases (decreases) for tax positions of prior years ​ ​ 89 ​ ​ - ​ ​ - Ending balance ​ $ 119 ​ $ - ​ $ - Interest and penalties ​ $ 65 ​ $ - ​ $ -

Principles of Consolidation a_2

Principles of Consolidation and Basis of Presentation - IPO and reorganization (Details) $ / shares in Units, $ in Thousands	Oct. 25, 2021USD ($)subsidiary$ / sharesshares	Dec. 31, 2021USD ($)shares	Dec. 31, 2021USD ($)itemshares	Dec. 31, 2020
Issuance of Class A common stock in the IPO, net of issuance costs | $		$ 259,710	$ 260,545
Preferred stock authorized		100,000,000	100,000,000
Employee profit percentage			2.00%	2.00%
Number of wholly-owned subsidiaries. | item			3
Pre-IPO common unitholders
Employee profit percentage	85.00%
Remaining tax savings retained	15.00%
IPO
Number of units acquired	5,526,607
Preferred stock authorized	100,000,000
Capital Units
Stock exchange ratio	1,000,000		1,000,000
Common Class A
Common stock, shares authorized		1,000,000,000	1,000,000,000
Common Class A | Pre-IPO Shareholders
Stock issued pursuant to acquisition (in shares)	48,744,182
Number of new wholly owned subsidiaries acquired | subsidiary	3
Common Class A | IPO
Stock issued (in shares)	21,562,500
Issue price per share | $ / shares	$ 17
Issuance of Class A common stock in the IPO, net of issuance costs | $	$ 259,700
Common stock, shares authorized	1,000,000,000
Common Class B
Common stock, shares authorized		150,000,000	150,000,000
Common Class B | IPO
Common stock, shares authorized	150,000,000
Enfusion LLC
Ownership Percentage		58.00%	58.00%

Principles of Consolidation a_3

Principles of Consolidation and Basis of Presentation (Details)	12 Months Ended
	Dec. 31, 2021segment
Principles of Consolidation and Basis of Presentation
Number of operating segments	1

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Allowances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounts Receivable, Allowance for Credit Loss
Beginning balance	$ 598	$ 95
Charges to the provision	1,450	1,010
Accounts written off, net of recoveries	(1,257)	(507)
Ending balance	791	598
Unbilled accounts receivable	$ 1,300	$ 349

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Useful life of property plant and equipment (Details)	12 Months Ended
	Dec. 31, 2021
Software development cost
Property, Plant and Equipment [Line Items]
Useful life	3 years
Computer equipment and software
Property, Plant and Equipment [Line Items]
Useful life	5 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Useful life	5 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Useful life	Shorter of estimated economic useful life or remaining lease term

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Disaggregation of revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Total revenues	$ 111,700	$ 79,565	$ 59,027
Revenues | Geographic Region
Disaggregation of Revenue [Line Items]
Total revenues	$ 111,700	$ 79,565	$ 59,027
Total net revenues percent	100.00%	100.00%	100.00%
Americas | Revenues | Geographic Region
Disaggregation of Revenue [Line Items]
Total revenues	$ 72,994	$ 54,057	$ 42,158
Total net revenues percent	65.30%	67.90%	71.40%
Europe, Middle East and Africa (EMEA) | Revenues | Geographic Region
Disaggregation of Revenue [Line Items]
Total revenues	$ 13,491	$ 8,748	$ 6,727
Total net revenues percent	12.10%	11.00%	11.40%
Asia Pacific (APAC) | Revenues | Geographic Region
Disaggregation of Revenue [Line Items]
Total revenues	$ 25,215	$ 16,760	$ 10,142
Total net revenues percent	22.60%	21.10%	17.20%
United States
Disaggregation of Revenue [Line Items]
Total revenues	$ 71,900	$ 53,000	$ 41,400

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	Oct. 25, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Impairment of long-lived assets		$ 0	$ 0	$ 0
Advertising cost		$ 1,200	$ 1,300	$ 464
Payment of fees upon invoice		30 days
Percentage of cash savings payable under tax receivable agreement		2.00%	2.00%
Deferred commissions		$ 1,700
Amortization expense		228
Revenue remaining performance obligation		$ 23,400
Pre-IPO common unitholders
Percentage of cash savings payable under tax receivable agreement	85.00%
Enfusion LLC
Ownership Percentage		58.00%
Ownership percentage by noncontrolling owners		42.00%
Minimum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Remaining performance obligation satisfaction period		1 year
Maximum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Remaining performance obligation satisfaction period		5 years

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property and Equipment, Net
Total property and equipment, cost	$ 21,516	$ 13,558
Less accumulated depreciation and amortization	(8,465)	(4,774)
Total property and equipment, net	13,051	8,784
Computer equipment and software
Property and Equipment, Net
Total property and equipment, cost	14,163	8,533
Software development costs
Property and Equipment, Net
Total property and equipment, cost	4,866	2,948
Leasehold improvements
Property and Equipment, Net
Total property and equipment, cost	1,947	1,406
Furniture and fixtures
Property and Equipment, Net
Total property and equipment, cost	$ 540	$ 671

Property and Equipment, Net - C

Property and Equipment, Net - Capitalized software development costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property and Equipment, Net
Property and equipment, net	$ 13,051	$ 8,784
Capitalized software development costs	2,000	1,400
Depreciation and amortization expense	2,400	1,500	$ 825
Amortization expense related to software development costs	1,300	759	$ 332
United States
Property and Equipment, Net
Property and equipment, net	$ 10,400	$ 7,500

Property and Equipment, Net - E

Property and Equipment, Net - Estimated future amortization of capitalized software development costs (Details) - Software development cost $ in Thousands	Dec. 31, 2021USD ($)
Property, Plant and Equipment [Line Items]
2022	$ 1,289
2023	863
2024	293
Total	$ 2,445

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued Expenses and Other Current Liabilities
Accrued compensation	$ 3,180	$ 5,261
Accrued expenses	1,182	1,478
Accrued taxes	1,216	414
Accrued interest		218
Current portion of deferred rent		29
Other current liabilities		266
Total accrued expenses and other current liabilities	5,578	7,666
Accrued compensation includes bonuses due to employees	$ 0	$ 3,600

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($) $ in Thousands	Oct. 25, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt
Repayment of term loan			$ 100,000	$ 300	$ 2,000
Unamortized debt issuance cost				1,400
Loss on extinguishment of debt	$ 1,200		1,215
Term Loan
Debt
Principal amount				$ 100,000
Quarterly principal payments		$ 1,250
Stated interest rate				5.25%
Term Loan | IPO
Debt
Repayment of term loan	$ 98,800
Revolving Debt | Second Amended Credit Agreement
Debt
Unused commitment amount			5,000	$ 4,800
Letter of credit
Debt
Letter of credit			$ 200	$ 200
Stated interest rate			2.00%	2.00%

Debt - Components of debt oblig

Debt - Components of debt obligations (Details) $ in Thousands	Dec. 31, 2020USD ($)
Debt
Term loan	$ 100,000
Less unamortized discount and issuance costs	(1,437)
Term loan, net	98,563
Less current portion	(2,500)
Long-term debt, net of discount and issuance costs	$ 96,063

Operating Leases and Service _3

Operating Leases and Service Agreements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating leases
2022	$ 4,384
2023	3,291
2024	2,385
2025	901
Total	10,961
Service agreements
2022	470
2023	19
Total	489
Total
2022	4,854
2023	3,310
2024	2,385
2025	901
Total	11,450
Expense related to lease agreements	3,900	$ 3,700	$ 2,500
Expense related to service agreements	1,100	$ 841	$ 425
Minimum
Operating Leases and Service Agreements
Monthly base payments	6
Maximum
Operating Leases and Service Agreements
Monthly base payments	$ 16

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Oct. 31, 2021
Employee profit percentage	2.00%	2.00%
Accrued Employee Net Profits	$ 347	$ 128
Common Class A | Share-based Payment Arrangement, Employee
Number of shares to be received in exchange for terminated employee agreements			2,047,064

Preferred Units Stockholders'_2

Preferred Units Stockholders' Equity and Members' Deficit (Details) $ in Thousands	Oct. 25, 2021	Dec. 31, 2021Voteshares	Dec. 31, 2020USD ($)shares
Class of Stock [Line Items]
Preferred units, outstanding (in shares)			53.774
Preferred units ownership percentage			52.85%
Preferred units carrying amount | $			$ 165,515
Units outstanding (in share)			47.968
Carrying value of equity | $			$ (233,347)
Total Preferred Units and Members' equity (deficit) , Outstanding (in shares)			101.742
Total Preferred Units and Members' equity (deficit) ,Percentage			100.00%
Total Preferred Units and Members' equity (deficit) | $			$ (67,832)
Preferred stock authorized		100,000,000
Common Class A
Class of Stock [Line Items]
Common stock, shares authorized		1,000,000,000
Number of Voting Rights | Vote		1
Common Class B
Class of Stock [Line Items]
Common stock, shares authorized		150,000,000
Number of Voting Rights | Vote		1
Class C-1 Units
Class of Stock [Line Items]
Preferred units, outstanding (in shares)			28.777
Preferred units ownership percentage			28.28%
Preferred units carrying amount | $			$ 6,434
Class C-2 Units
Class of Stock [Line Items]
Preferred units, outstanding (in shares)			12.219
Preferred units ownership percentage			12.01%
Preferred units carrying amount | $			$ 44,863
Class D Units
Class of Stock [Line Items]
Preferred units, outstanding (in shares)			12.778
Preferred units ownership percentage			12.56%
Preferred units carrying amount | $			$ 114,218
Class A Units
Class of Stock [Line Items]
Units outstanding (in share)			47.968
Equity ownership percentage			47.15%
Carrying value of equity | $			$ (233,347)
Capital Units
Class of Stock [Line Items]
Stock exchange ratio	1,000,000	1,000,000

Management Incentive Plan and_3

Management Incentive Plan and Stock-based compensation - Narratives (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Management Incentive Plans
Share-based Payment Arrangement, Expense		$ 289,803
Payment of tax withholding obligations for federal payroll taxes		15,100
Payment for employee payroll tax withholding obligations on stock-based compensation		$ 10,567
Percentage of Increase in Shares Outstanding Annually	3.00%
Options granted to employees		0
Restricted Stock Units
Management Incentive Plans
Outstanding		4,595,363	0
Vested (in years)	4 years
Issued units		22,213,282
Pre-IPO Plan
Management Incentive Plans
Shares, Authorized			1,000,000
Outstanding			22.941
Issued units			22.941
2021 ESPP
Management Incentive Plans
Percentage of Increase in Shares Outstanding Annually	1.00%
Common Class A
Management Incentive Plans
Common stock reserved for future issuance	26,400,000
Common Class A | Share-based Payment Arrangement, Employee
Management Incentive Plans
Number of shares to be received in exchange for terminated employee agreements	2,047,064
Fair value of shares to be issued in exchange of termination of employment agreements	$ 31,200
Common Class A | IPO
Management Incentive Plans
Vested (in years)	1 year
Share-based Payment Arrangement, Expense	$ 237,300
Common Class A | 2021 ESPP
Management Incentive Plans
Shares, Authorized	150,000
Purchase price of common stock, percent	85.00%
Maximum | Restricted Stock Units
Management Incentive Plans
Vested (in years)	4 years

Management Incentive Plan and_4

Management Incentive Plan and Stock-based compensation - Assumptions for Performance-based shares (Details) - Restricted Stock Units	Oct. 20, 2021$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of common stock (per share)	$ 17
Expected volatility	48.20%
Risk-free interest rate	1.65%
Expected dividend yield	0.00%
Cost of equity capital	11.20%

Management Incentive Plan and_5

Management Incentive Plan and Stock-based compensation - Restricted Stock Units (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Class A common stock vested
Restricted Stock Units
Total granted during the period	17,582,780
Class A common stock contingently issued
Restricted Stock Units
Total granted during the period	1,725,708
Restricted Stock Units
Restricted Stock Units
Beginning Balance	0
Total granted during the period	22,213,282
Forfeited during the period	(35,139)
Shares redeemed for satisfaction of tax obligations	(621,510)
Outstanding	21,556,633
Vested as of 12/31/2021	16,961,270
Ending Balance	4,595,363
Weighted Average Fair Value per RSU at Grant Date
Beginning Balance | $ / shares	$ 0
Total granted during the period | $ / shares	15.53
Forfeited during the period | $ / shares	16.85
Shares redeemed for satisfaction of tax obligations | $ / shares	15.27
Outstanding | $ / shares	15.57
Vested as of 12/31/2021 | $ / shares	15.27
Ending Balance | $ / shares	$ 16.46
Restricted Stock Units | Pre-IPO Plan
Restricted Stock Units
Total granted during the period	2,260,168
Restricted Stock Units | Pre-IPO Plan | Market condition
Restricted Stock Units
Total granted during the period	94,116
Restricted Stock Units | Pre-IPO Plan | Service condition
Restricted Stock Units
Total granted during the period	2,166,052
Restricted Stock Units | 2021 Plan
Restricted Stock Units
Total granted during the period	644,626

Management Incentive Plan and_6

Management Incentive Plan and Stock-based compensation - Equity-Based Compensation (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Management Incentive Plans
Total stock compensation expense	$ 289,803
Class A common stock vested
Management Incentive Plans
Total stock compensation expense	268,500
Restricted Stock Units And Class A Common Stock Vested
Management Incentive Plans
Unrecognized stock compensation expense	$ 54,200
Stock based compensation recognition period	2 years
Cost of revenues
Management Incentive Plans
Total stock compensation expense	$ 377
General and administrative
Management Incentive Plans
Total stock compensation expense	112,829
Sales and marketing
Management Incentive Plans
Total stock compensation expense	36,312
Technology and development
Management Incentive Plans
Total stock compensation expense	$ 140,285

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Benefit Plans
Contribution percent of employees	50.00%
Contribution percent of match	3.00%
Employer discretionary contribution Amount	$ 45	$ 345	$ 241

Net Income (Loss) Per Class A_3

Net Income (Loss) Per Class A Common Share - Diluted net loss per common unit (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net loss	$ (282,242)	$ 4,061	$ 12,656
Less: Net income attributable to Enfusion, Inc. prior to the IPO	(12,892)
Less: Net loss attributable to non-controlling interests subsequent to the IPO	123,925
Net loss attributable to Enfusion, Inc.	(171,209)
Adjustment to income (loss) attributable to common stockholders	(16,580)
Numerator for Basic Earnings per Share	$ (187,789)
Denominator:
Weighted-average shares of Class A common stock outstanding	65,583
Vested shares of Class A common stock	17,462
Weighted-average shares of Class A common stock outstanding--basic	83,045
Net loss per share of Class A common stock-basic	$ (2.26)
Net loss per share of Class A common stock- diluted	$ (2.26)

Net Income (Loss) Per Class A_4

Net Income (Loss) Per Class A Common Share - Dilutive shares (Details)	12 Months Ended
	Dec. 31, 2021shares
Antidilutive securities amount	52,102
Common Class B
Antidilutive securities amount	47,471
Contingently issuable shares of Class A common stock
Antidilutive securities amount	1,726
Restricted Stock Units
Antidilutive securities amount	2,905

Income Taxes - Components of in

Income Taxes - Components of income (loss) before income taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes
U.S.	$ (279,990)	$ 3,130	$ 12,231
Foreign	(1,673)	1,364	911
(Loss) income before income taxes	$ (281,663)	$ 4,494	$ 13,142

Income taxes - Components of _2

Income taxes - Components of income tax expense (benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current tax expense
Foreign	$ 228	$ 433	$ 486
Total current tax expense	228	433	486
Deferred tax (benefit) expense
Foreign	351
Total Deferred Income Tax (Benefit) Expense	351
Total	$ 579	$ 433	$ 486

Income taxes - Effective income

Income taxes - Effective income tax rate reconciliation (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes
At U.S. Federal statutory tax rate	21.00%	21.00%	21.00%
State Tax, Net of Federal Benefit	4.28%
Noncontrolling Interest	9.20%
Foreign Branch Taxes	(0.28%)	9.64%	3.70%
Equity Based Compensation	(2.49%)
Foreign Rate Differential	0.04%	(1.14%)	(0.42%)
Valuation allowance	(14.51%)
Pass-through Loss (Income)	0.91%	(19.86%)	(20.58%)
Other	0.04%
Total	(0.21%)	9.64%	3.70%

Income taxes - Components of de

Income taxes - Components of deferred tax assets and liabilities (Details) $ in Thousands	Dec. 31, 2021USD ($)
Deferred tax assets
Investment in Enfusion Ltd. LLC	$ 80,124
Equity Based Compensation	38,362
Net Operating Losses	5,475
Other	565
Total deferred tax assets	124,526
Valuation allowance	(124,526)
Total deferred tax assets, net of valuation allowance	0
Deferred tax liabilities
Property, plant and equipment	(351)
Total Deferred tax liabilities	(351)
Net Deferred Tax Liabilities	$ (351)

Income taxes - Unrecognized def

Income taxes - Unrecognized deferred taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Uncertain tax positions
Beginning balance	$ 0
Increases for tax positions related to the current year	30
Increases (decreases) for tax positions of prior years	89
Ending balance	119
Interest and penalties	$ 65	$ 0	$ 0

Income taxes - Narratives (Deta

Income taxes - Narratives (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Tax benefit attributable to noncontrolling interest	$ 25,900
Tax impact of equity-based compensation	2,500
Net Deferred Tax Benefit	40,800
Foreign income taxes related to pre-tax income of its branch	600	$ 400	$ 500
Valuation Allowance [Abstract]
Valuation allowance	124,526
Valuation allowance recorded in additional paid-in capital	83,100
Net loss carryforward	$ 18,400
Percentage of Entity's Share of Tax Benefits Under Tax Receivable Agreement	85.00%
Percentage of Other's Share of Tax Benefits Under Tax Receivable Agreement	15.00%
Tax liability of a position taken if determined to be reasonably possible under the Tax Receivable Agreement.	$ 74,700
Enfusion LLC
Operating Loss Carryforwards [Line Items]
Tax impact of the pre-tax book income	$ 2,600	$ 900	$ 2,700
Valuation Allowance [Abstract]
Number of units purchased in connection with Pre-IPO	5,526,607
Tax Receivable Agreement, Obligations	$ 87,800

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Millions	Dec. 24, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 23, 2020
Related Party Transaction [Line Items]
Preferred units, outstanding (in shares)			53.774
Class D Units
Related Party Transaction [Line Items]
Preferred units, outstanding (in shares)			12.778
Issuance of class units net of issuance cost (in shares)	7.964
Purchase price per unit	$ 11.7
Issuance of class units	$ 93.5
Class D Units | FTV Enfusion Holdings, Inc
Related Party Transaction [Line Items]
Exchanged units (in shares)	4.814
Issuance of class units net of issuance cost (in shares)	4.814
Issuance of class units	$ 56.5
Class C-2 Units
Related Party Transaction [Line Items]
Preferred units, outstanding (in shares)			12.219
Class C-2 Units | FTV Enfusion Holdings, Inc
Related Party Transaction [Line Items]
Preferred units, outstanding (in shares)				7.494
Repurchased units (in shares)	0.898
Class C-1 Units
Related Party Transaction [Line Items]
Preferred units, outstanding (in shares)			28.777
Class C-1 Units | FTV Enfusion Holdings, Inc
Related Party Transaction [Line Items]
Preferred units, outstanding (in shares)				32.693
Repurchased units (in shares)	3.916
IPO
Related Party Transaction [Line Items]
Purchase Of Common Units		5,526,607
Payments To Acquire Newly Issued Common Units		$ 87.8